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To assess the risk of non-syndromic orofacial cleft after exposure to macrolides, antifungals, 
and antivirals/ antiretrovirals during pregnancy.   
Search Strategy: 
MEDLINE, EMBASE, and the Cochrane library were searched up to April 30, 2019.  
Search Criteria: 
Relevant English language studies investigating foetal adverse outcomes after in utero 
exposure to macrolides, antifungals, and antivirals/ antiretrovirals. 
Data Collection and Analysis: 
Studies were screened by two reviewers. Data was extracted, study quality was assessed, 
and pooled estimates were calculated. A random effects meta-analysis was conducted to 
estimate the effect of macrolides and antifungals on the risk of developing a cleft. 
Antivirals/ antiretrovirals were not included in the meta-analysis as it was not possible to 
extract the data from the papers identified. 
Main Results: 
Overall, nine case-control studies and eight cohort studies met the inclusion criteria. Eight of 
the seventeen studies were included in the meta-analysis having excluded those pertaining 
to antivirals/ antiretrovirals and limiting to those measures that were either an “Odds Ratio” 
or “Prevalence Odds Ratio”. The data indicated that erythromycin and fluconazole exposure 
during pregnancy is not associated with an increased risk of cleft lip and palate. For 
antivirals and antiretrovirals, no conclusion could be reached due to the high level of 




Exposure to macrolides and antifungals was not associated with an increased risk of oral 
cleft. Further studies are required to investigate whether antivirals and antiretrovirals pose 
a risk during pregnancy.
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Cleft lip and palate (CLP) is a common congenital malformation in humans, which arises 
during facial development. The aetiology is unknown, but like other disorders, it is likely to 
have both genetic and environmental influences (Mossey et al., 2009; Dixon et al., 2011). 
Orofacial clefts (OFC) can present as either an isolated trait or as part of a syndromic 
condition. Treatment of these congenital malformations is crucial and requires 
comprehensive medical and behavioural interventions, causing both a psychosocial and 
economic burden among the affected individual and their families (Wehby and Cassell, 
2010). 
During embryonic development, the maternal environment is crucial and is influenced by 
nutrition, medications, and lifestyle. In the first trimester of pregnancy the craniofacial 
complex develops, and either deficits or excesses of nutritional intake during the first 
trimester of pregnancy can influence the formation of CLP. Therefore, for pregnant women 
or women trying to conceive, a diet high in folate or folic acid supplements is recommended 
with avoidance of excessive intake of vitamin A (Loffredo et al., 2001; Rothman et al., 1995).  
The adverse effects of medicinal intake on CLP are not as clear cut. The literature contains a 
mix of methodologies and investigations in determining what influence medications might 
have in the formation of cleft. This systematic review and meta-analysis aimed to 
investigate whether in utero foetal exposure to macrolides, antifungals, or antivirals/ 
antiretrovirals is associated with an increased risk of non-syndromic orofacial clefts (NSOFC). 




2.0 REVIEW OF THE LITERATURE 
2.1 Cleft Lip and Palate 
A cleft is a gap in the upper lip, the palate, or a combination of these structures.  Orofacial 
clefts are categorised as syndromic if they are associated with other congenital 
abnormalities (CAs), or NSOFC if they occur in isolation with no other structural or 
developmental abnormalities. Some of the syndromes that have been associated with CLP 
include: Van der Woude, Pierre Robin sequence, Treacher Collins, Stickler, and 22q11 
deletion syndrome (Cohen, 1978). Orofacial clefts develop due to a failure of closure of 
specific facial structures during weeks 5-9 of gestation (vide infra 2.3 and 2.4).  
Moreover, clefts vary in severity and present as different phenotypes: isolated cleft lip (CL), 
isolated cleft palate (CP), and CLP. Approximately 70% of cleft lip with or without cleft palate 
(CL/P) cases and 50% of CP cases are non-syndromic (Mossey et al., 2009). Clefts can be 
further classified according to the extent of tissue involvement: unilateral, bilateral, 
incomplete, and complete (Mossey et al., 2009). As illustrated in Figure 1, CL/P affecting one 
side of the face is said to be unilateral, whereas bilateral affects both sides. Complete cleft 
refers to a cleft affecting the entire anatomical structure, such as the lip, alveolus, and/or 
palate. Incomplete cleft, on the other hand, involves only part of these structures. 
Incomplete cleft may present as a notch in the lip and/or alveolus, or a cleft involving only a 
portion of the palate. A minor form of CL, known as microform CL, may also develop. This 




Figure 1  Phenotypes of CLP.  
(A) CL and alveolus. (B) CP. (C) Incomplete unilateral CLP. (D) Complete unilateral CLP. (E) 
Complete bilateral CLP. (Source: Mossey et al., 2009)  
2.2 Epidemiology  
Oral cleft (OC) is one of the most common birth defects among humans. According to the 
World Health Organization (WHO) in 2001, every two minutes somewhere in the world a 
child is born with some form of cleft, and it occurs in about 1 in every 700 live births 
(Mossey and Castillia, 2003). This varies according to ethnicity, with Native American Indians 
having the highest incidence of CL/P with 3.6 in every 1000 livebirths, followed by the 
Japanese with 2.1 in every 1000 livebirths (Croen et al., 1998). In Caucasians, the incidence 
of OFC is reasonably constant with 1:800 to 1:1000 for CLP and 1:800 for CP (Fraser, 1970; 
Bonaiti et al., 1982; Gorlin et al., 2001). There is also a gender influence with CL/P being 
more common in males, while isolated CP is more common in females (Mossey and Little, 
2002). Bilateral clefts are more severe than unilateral clefts. Fortunately, they occur less 
frequently, comprising only 10% of all clefts (Bender, 2000). In terms of laterality, left-sided 
clefts are more common than right-sided clefts and are associated with lower levels of 
academic performance than individuals with right-sided clefts, who showed similar 
performance to their unaffected classmates (Gallagher et al., 2017). Table 1 summarises the 






Sex  CL/P: M > F 
CP: F > M 
Site CL: 20% 
CLP: 46% 
CP: 33% 
Laterality of CL Unilateral CL: 
• Left > Right (2:1) 
• Unilateral > Bilateral (9:1) 
• Associated with CP in 68% of cases 
Bilateral CL: 
• Associated with CP in 86% of cases 
Types of CL Microform (presence of vertical groove and vermillion 
notching) 
Unilateral CL (complete or incomplete)  
Bilateral CL 
Types of CP CP associated with CL 
Isolated CP  
• CP (hard or soft palate) 
Submucous CP 
Table 1 Clinical features of cleft. (Source: Chen, 2006) 
2.3 Embryonic Development  
Development of the orofacial structures is a complex process involving several stages, 
namely: cell migration, growth, differentiation, and apoptosis. These key stages of 
embryonic development require critical regulation.  
2.3.1 Facial Development   
During the 4th week of human embryonic development, neural crest cells migrate through 
the mesenchyme to the developing craniofacial region and form the five primitive facial 
processes: frontonasal process, right and left maxillary processes, and right and left 
mandibular processes. These facial processes containing mesenchyme, surrounded by an 
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epithelial barrier, merge to form the orofacial structures, as illustrated in Figure 2. Two 
theories exist on how these facial processes unite. One theory explains that as one facial 
process approximates another, the epithelial layer resorbs and the two processes “fuse” 
together. The other theory states that these processes correspond to mesenchymal growth 
centres that lead to “merging” of the processes rather than fusion (Streeter, 1948). 
 
Figure 2 Development of the lip and palate. 
(a) The frontonasal prominence and paired maxillary and mandibular processes surround 
the oral cavity. (b) The medial and lateral nasal processes develop. (c) The medial nasal 
processes unite to form the philtrum, primary palate, and maxillary incisors. The medial and 
maxillary processes unite to form the rest of the upper lip, and the medial, lateral and 
maxillary processes unite to form the alae of the nose. (d) The maxillary processes extend 
bilaterally to form the palatal shelves. (e) The palatal shelves elevate and merge to form the 
secondary palate. (f) This fusion creates two cavities: the oral and nasal cavities. (Source: 
Dixon et al., 2011) 
2.3.2 Lip Development 
The development of the lip occurs during the 5th and 6th weeks in utero. The lip is formed by 
fusion of the maxillary processes below the lateral nasal processes. As the maxillary 
processes grow in a medial direction, they merge with the medial nasal processes to form 
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the philtrum and tissues of the upper lip. Failure of fusion of these processes may result in a 
CL. 
2.3.3 Palate Development 
Palate development, or palatogenesis, takes place at the end of the 5th week of embryonic 
development and consists of two parts: 
• Development of the primary palate 
• Development of the secondary palate 
The medial nasal processes unite to form the primary palate, which in turn gives rise to the 
four upper incisors and the surrounding alveolar bone. The secondary palate, on the other 
hand, develops as a result of fusion of the maxillary processes. This union gives rise to the 
remaining maxillary teeth as well as the hard and soft palate.  
During embryonic development, the hard palate develops as two separate halves, which 
extend from the anterior border of the lips to the posterior border of the uvula. The palatal 
shelves, on either side of the tongue, grow vertically and elevate to a horizontal position 
above the dorsum of the tongue (Sandy and Brown, 2002). This elevation occurs as a result 
of one or both of the following mechanisms:  
1. Extrinsic forces – movement of the tongue, increase in the size of the mandibular 
prominence, lifting of the head, straightening of the cranial base, and an increase in 
the height of the oronasal cavity. 
2. Intrinsic forces – change in the osmotic pressure, muscular and non-muscular 
contractions, cellular reorganisation, and vascular forces. 
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In normal development, the palatal shelves fuse creating a continuity in the underlying 
mesenchyme. For the palatal shelves to fuse, the medial epithelial seam breaks down either 
by apoptosis (Cuervo and Covarrubias, 2004; Vaziri Sani et al., 2005) or by transformation of 
the epithelium into mesenchyme (Sun et al., 2000; Nawshad and Hay, 2003). In 2007, 
Ahmed et al. showed that both epithelial transformation and apoptosis are necessary for 
fusion of the palatal halves to take place. Lack of fusion of one or more of these tissues will 
result in CP.  
Table 2 summarises embryonic orofacial development, including the lip and palate. It clearly 
shows what facial processes fuse or merge together to form the corresponding facial 
structures.   
Facial Processes Facial Structures 
Mandibular process + mandibular process Lower lip 
Lower part of cheeks  
Other mandibular structures  
Medial nasal processes + maxillary processes Philtrum 
Primary palate 
Maxillary incisors 
Surrounding alveolar bone 
Maxillary process + maxillary process Upper lip 
Secondary palate 
Upper part of cheeks 
Lateral + medial nasal processes + maxillary process  Ala of nose 
Table 2 Orofacial development. (Source: Sandy and Brown, 2004; Cobourne and DiBiase, 
2015)  
2.4 Pathophysiology  
Cleft lip develops because of a failure of part of the frontonasal process, medial and lateral 
nasal processes, and the maxillary process to unite. For a unilateral cleft of the lip to 
develop, the maxillary process on one side fails to unite with the merged medial nasal 
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processes. Whereas, for a bilateral CL to develop, the same disruption takes place in both 
maxillary processes. Cleft palate, on the other hand, develops either because of failure of 
the medial nasal processes to unite, failure of the maxillary processes to unite, or a 
combination of both (Moore and Persuad, 1993).  
In summary, CL/P develops due to: 
• Failure of fusion of facial processes 
• Failure of elevation of one or both palatal shelves 
• Failure of epithelial breakdown between the palatal shelves 
2.5 Aetiology 
Cleft lip with or without cleft palate is said to be of multifactorial or polygenic inheritance 
meaning that the condition is caused by both genetic and environmental factors. These 
genetic abnormalities and/or environmental disturbances alter the composition of the 
extracellular matrix (ECM), affecting cell patterning, migration, proliferation, and 
differentiation. This in turn may result in failure of fusion or merging of the facial processes 
causing an OFC to develop (Young et al., 2000). 
Carinci et al. in 2007 stated that any changes in the distribution of ECM components, 
cytokines, and growth factors (GF), such as fibroblast growth factor (FGF) 2 and 
transforming growth factor (TGF) beta-3 (TGFβ-3), may affect the regulation of the complex 
events that take place during cranial and orofacial development.  
Extracellular matrix is especially crucial for the development of the palate. The molecules of 
the ECM activate GF and cytokines present in the epithelial cells and palatal mesenchyme 
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(Qiu and Ferguson, 1995). Therefore, any disturbances in the ECM may give rise to CP. 
Mutations and/or deficiencies in TGFβ-3 may also give rise to CP (Lidral et al., 1998).  
2.5.1 Genetic Factors 
Linkage and association studies have played a major role in the identification of genes 
associated with the development of OFC (Adeyemo and Butali, 2017). Linkage is used to 
identify specific mutations that are common among all affected individuals (Teare and 
Barrett, 2005). This is done by comparing affected chromosomes with those of unaffected 
individuals. Association, on the other hand, is used to identify chromosomal segments when 
not much is known about the affected individual (Cordell and Clayton, 2005). Some of these 
identified genes include TGF beta (TGFβ) (Ardinger et al., 1989), MSX1 (Jezewski et al., 2003; 
Butali et al., 2011), and AP2 (Rahimov et al., 2008).   
Another way of identifying the genes that cause cleft is by using mouse models with the 
insertion and deletion of specific genes. The three most common examples of knockouts 
are: 
1. MSX1 (Satokata and Maas, 1994; Houzelstein et al., 1997) 
2. TGFβ-3 (Proetzel et al., 1995; Kaartinen et al., 1995) 
3. AP2 (Notolli et al., 1998) 
Expression of these genes is involved in craniofacial development and thus, their knockout 
results in clefts. Mutations in MSX1 and TGFβ-3 have been shown to result in CP. Whereas, 




The risk of inheriting CL/P increases with an increase in the severity of the phenotype, 
degree of kinship, and number of affected relatives. The greater the number of individuals 
affected, the greater the chance of inheriting CL/P (Bender, 2000). Evidence indicates a 
strong genetic influence on the development of NSOFC with a heritability rate of more than 
90%, and if a first-degree relative is affected, the risk increases by 30 to 40 folds (Sivertsen 
et al., 2008; Grosen et al., 2010). Studies on siblings and twins have helped to clarify the 
inheritance pattern of NSOFC and the influence of genetic factors. The risk of having a baby 
with CL/P is higher among monozygotic twins (identical) than dizygotic twins (non-identical), 
with a rate of 40-60% and 5% respectively (Murray, 2002). Since the concordance rate 
among monozygotic twins is not 100%, this suggests that genetic factors alone are not the 
only aetiological factor responsible for the development of OFC. 
2.5.2 Environmental Factors 
Although the exact cause of NSOFC remains unknown, it has been associated with several 
risk factors. Some of the major risk factors include maternal smoking, alcohol consumption, 
nutritional intake, fever, medical conditions, use of medication, illicit substances, exposure 
to occupational hazards, obesity, and socioeconomic status.  These will now be described. 
2.5.2.1 Smoking 
There is evidence of a significant association between maternal smoking and CL/P, especially 
during the first trimester. In an analysis of 4,268 cases in China, smoking was shown to be 
the second greatest risk factor of OFC during the first trimester of pregnancy (Meng et al., 
2006). Two systematic reviews and meta-analyses by Wyszynski et al. (1997) and Little et al. 
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(2004), based on 11 and 24 studies respectively, showed a statistically significant association 
between maternal smoking and NSOFC. Sabbagh et al. (2015) updated these systematic 
reviews, and ominously concluded that a 1.5-fold increase risk of NSOFC results with passive 
maternal smoking, which is the same risk as those that actively smoke. 
There is also evidence on the intensity of smoking and whether this influences the 
development of CL/P. Most studies classified the intensity at two levels: low (1-9 cigarettes 
per day) and medium (10+ cigarettes per day) (Ericson et al., 1979; Romitti et al., 1999; 
Lorente et al., 2000). Others have described three levels: low (1-10 cigarettes per day), 
medium (11-20 cigarettes per day), and high (21+ cigarettes per day) (Czeizel and Nagy, 
1986; Khoury et al., 1987). Little et al. (2004) analysed eight studies that had sufficient 
information to perform a dose-response analysis. Four of the eight studies had a weak 
positive dose-response relationship, and the remainder showed no relationship at all. It was 
concluded that there was no strong evidence to correlate the dose of cigarette smoking to 
the risk of OFC development.  
2.5.2.2 Alcohol 
Alcohol is a known teratogen that can cause a wide range of foetal defects. One of the most 
severe is foetal alcohol syndrome (FAS), characterised by CAs, growth retardation, and 
central nervous system disorders (Clarren and Smith, 1978). Cleft lip with or without cleft 
palate occurs in 9-18% of individuals with FAS. However, CL/P is not characteristic of this 
syndrome (Abel, 1998).  
Measuring alcohol consumption is difficult and mainly comprises self-reporting. There are 
inconsistencies due to the vagueness in the type and amount of alcohol consumption 
recorded. Some evidence shows that even with low levels of alcohol, there is a significant 
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increase in the risk of developing OFC (Munger et al., 1996). While other studies have found 
that there is no risk of developing cleft with low levels of alcohol, but increased risk with 
high levels (Werler et al., 1991; Shaw and Lammer, 1999).  
Many studies have shown consistent results when it comes to binge drinking; that is 
drinking five or more units of alcohol per sitting. There is an increase in the risk of a foetus 
developing a cleft when mothers engage in binge drinking during pregnancy (Gladstone et 
al., 1996). A case-control study in Norway in 2008 studied 377 participants with CL/P and 
196 with isolated CP. They found that when compared with women who did not drink, 
women who binge drink had a greater risk of having infants with CL/P (Deroo et al., 2008).  
2.5.2.3 Nutritional Intake 
Nutritional intake during pregnancy has been identified as a factor in the aetiology of OFC 
(Shaw et al., 2006). However, the extent to which each nutrient is associated with CL/P 
remains unknown.  
2.5.2.3.1 Folic Acid 
The association between maternal intake of folic acid has been studied and the evidence is 
inconsistent. It is highly likely that folic acid intake varies greatly between populations, but 
several studies have shown that mothers who take vitamin supplements containing folic 
acid have a reduced risk for an infant to be born with CL/P (Shaw et al., 1995; Bailey and 
Berry, 2005; Wilcox et al., 2007). Wehby et al. (2013) conducted the first double-blinded 
randomised control trial studying the effects of high and low doses of folic acid in women 
who were born with a cleft or had a child with a cleft. The OC recurrence rates were 2.9% 
and 2.5% in the 0.4 and 4 mg of folic acid groups, respectively. The results were similar 
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between the two folic acid groups, suggesting that there is no clinically significant difference 
in the dose of folic acid and the development of CL/P. However, the trial was underpowered 
due the high number of withdrawals and terminations. This means that there was 
insufficient statistical power to detect the smallest difference in recurrence rates between 
the low and high dose groups.  
A systematic review, updated in the Cochrane database in 2015, entitled “Effects and Safety 
of Periconceptional Oral Folate Supplementation for Preventing Birth Defects” concluded 
that folic acid can prevent neural tube defects. However, its effect on specific birth defects, 
such as CL/P is not clear (De-Regil et al., 2015).  
2.5.2.3.2 Vitamin B 
Although folic acid has been the main nutritional intake investigated, other nutrients have 
also been studied and have been found to contribute to lowering the risk of developing OFC. 
After comparing the intake of mothers of infants with NSOFC to controls, Krapels et al. 
(2004) concluded that periconceptional maternal intake of vitamin B, including thiamine, 
niacin, and pyridoxine, significantly reduces the risk of NSOFC. However, this may be 
because of confounding factors, such as folic acid, or simply because these mothers who are 
exposed to these vitamins live healthier lifestyles with a dietary intake high in vitamin B. 
Vitamin B contributing to the prevention of NSOFC has also been confirmed in animal 
experiments. In one study by Schubert et al. (2002), murine strains were given high levels of 
vitamin B, and as a result, these strains had a lower incidence of OFC.   
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2.5.2.3.3 Vitamin A 
Retinol, also known as vitamin A, is commonly used to treat various dermatological 
conditions and has been associated with several congenital malformations, one of which is 
foetal retinoid syndrome (FRS). One of the craniofacial abnormalities that may be present in 
infants with FRS is CL/P. The teratogenicity of vitamin A from both diet and supplements 
was studied in a prospective cohort study consisting of 22,748 pregnant women in Boston. 
The authors concluded that high dietary intake of vitamin A is potentially teratogenic. It was 
also estimated that about 1 in every 57 infants exposed to vitamin A had a malformation, 
including OC (Rothman et al., 1995).  
Teratogenicity of retinoids has been linked to oral intake, but it may be teratogenic when 
used topically during pregnancy, as well. A systematic review and meta-analysis by Kaplan et 
al. (2015) found no increase in the rates of major congenital malformations (MCMs), 
spontaneous abortions, low birthweight, or premature delivery when retinoids were used 
topically. This is reassuring to women who have been exposed to topical retinoids when 
they were not aware of their pregnancy. However, due to the low statistical power of the 
study, topical retinoids should be cautiously prescribed during pregnancy (Kaplan et al., 
2015). 
2.5.2.3.4 Zinc 
Antioxidants, such as zinc, have been studied and seem to be associated with lower levels of 
OFC (Tamura, et al., 2005; Wallenstein, et al., 2013). However, a true causal relationship 
cannot be deduced as zinc concentration in plasma is affected by a number of external 
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factors. Some of which include exercise, trauma, infection, inflammation, as well as the time 
when the blood sample was taken and the time of the last meal. 
2.5.2.4 Infection and Fever 
Exposure to infection and fever during pregnancy has been suggested to have an association 
with a higher risk of CL/P. Wang et al. (2009) concluded that a history of fever or cold during 
the first trimester of pregnancy is associated with an approximate threefold increase of OFC. 
This causal finding is consistent with two other previous studies (Hakosalo and Saxen, 1971; 
Zhang and Cai, 1993). A systematic review (17 papers) on adverse outcomes for infants 
where mothers had a history of fever during pregnancy, confirmed that there is an 
association between gestational fever and congenital anomalies, especially neural tube 
defects, congenital heart defects, and OC (Dreier et al., 2014).  
2.5.2.5 Medical Conditions and Related Medication 
This dissertation will focus on the effects of medication, specifically macrolides, antifungals, 
and antivirals/ antiretrovirals, taken during pregnancy on CL/P. Therefore, most of the 
information related to this heading will be presented later in the discussion and briefly in 
the literature review.  
2.5.2.5.1 Hyperthyroidism  
A number of studies have investigated the effects of antithyroid drugs on the risk of 
congenital anomalies, one of which is CL/P. Hyperthyroidism affects 0.2%-2.7% of 
pregnancies worldwide (Li et al., 2015). Antithyroid drugs, such as propylthiouracil (PTU), 
methiamazole (MMI), and carbimazole (CMZ), are considered the drugs of choice for 
hyperthyroidism during pregnancy, although it is well known that these drugs do have a 
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tendency to cross the placenta and influence foetal development. A meta-analysis (eight 
studies) showed that when pregnant women are exposed to PTU or MMI/CMZ there is an 
increased risk of their children developing congenital anomalies (Li et al., 2015). These 
results were consistent with a systematic review published the year before (Laurberg and 
Andersen, 2014).   
2.5.2.5.2 Asthma 
Asthma is another common condition that affects pregnant women with approximately 8.4-
8.8% reporting asthma (Kwon et al., 2006). Asthma is treated with ant-inflammatory drugs, 
such as corticosteroids, mast cell stabilisers, and leukotriene modifiers, as well as 
bronchodilators such as 2-adrenergic agonists, anticholinergic agents, and theophylline. 
Asthmatic women are at a greater risk of adverse pregnancy outcomes (Demissie et al., 
1998; Tamasi et al., 2006). Despite these known facts, the National Education and 
Prevention Program (NAEEP) still recommends the continuation of asthma medication 
throughout the course of the pregnancy (NAEEP, 2005).  
Oral corticosteroids have been found to contribute to the development of CL/P when taken 
during the first trimester (Park-Willie et al., 2000; Carmichael et al., 2007), as do 
bronchodilators. In a study performed on pregnant mice and rabbits, bronchodilators were 
administered to assess whether these drugs influenced the development of CP. They 
concluded that there is a statistically significant association between maternal 
bronchodilator use and CL/P (Szabo et al., 1975; Shibata et al., 2000). A similar case control 




Obesity is a major health problem and an economic burden. Pre-pregnancy maternal obesity 
can influence both the mother and the child. Mothers may develop gestational diabetes and 
hypertensive disorders, such as preeclampsia. Infants of obese mothers on the other hand, 
are at increased risk of birth complications, perinatal death, and congenital anomalies. A 
systematic review and meta-analysis assessed the relationship between maternal obesity 
and the risk of congenital anomalies. Obese mothers are at significantly increased risk of 
having an infant with CLP or isolated CP when compared with mothers of recommended 
body mass index (BMI), but this was not the case for isolated CL (Stothard et al., 2009). 
2.5.2.5.4 Diabetes Mellitus  
Pregnant women who are both obese and diabetic are three times more likely to have an 
infant with craniofacial anomalies (Moore et al., 2000) including OFC (Spilson et al., 2001). In 
a cross-sectional observational study of 325 mothers with a child with CLP, the prevalence 
of diabetes mellitus (DM) was 27%, which is significantly higher than the general Brazilian 
population of 7.6%. In addition to its association with CLP, DM also increases the risk of 
other craniofacial anomalies (Trindade-Suedam et al., 2016).  
2.5.2.6 Illicit Substances 
The prevalence of prenatal illicit substance abuse in the United States of America ranges 
from 6.2% to 12.4% (Arria et al., 2006; Bauer et al., 2005; Behnke et al., 2001; El-Mohandes 
et al., 2003). Determining the true association between maternal drug abuse and adverse 
foetal outcomes is challenging because drug abuse is usually accompanied by other 
confounding factors, such as smoking and alcohol. Furthermore, the sample size is usually 
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small because not everyone recruited to a study will admit to taking part in what is 
considered an illegal behaviour. Fear of judgement and prosecution underestimates the true 
outcome of these studies.  
Mothers who use illicit drugs during their pregnancy are three times more likely to give birth 
to children with CL/P in association with other congenital anomalies, than mothers who do 
engage in these recreational habits (Trindade-Suedam et al., 2016). Based on the evidence 
available, marijuana does not appear to be associated with major congenital anomalies (Lee, 
1998; Witter and Niebyl, 1990). However, cocaine seems to have a major influence on 
congenital anomalies. Using data from the National Birth Defects Prevention Study, an 
association was found between periconceptional cocaine use and the development of CP 
(van Gelder et al., 2009). Cocaine is known to cause vasoconstriction and sudden 
hypertension. This in turn interrupts blood flow to certain tissues of the embryo, leading to 
CP formation. It can also be speculated that certain illicit substances when taken together 
can potentiate their effects in causing congenital anomalies to develop.  
No relevant animal studies have been carried out investigating cocaine. However, marijuana 
use during pregnancy has been shown to cause neural tube defects in rabbits and hamsters, 
which is not the case in human studies (Geber and Schramm, 1969). 
2.5.2.7 Occupational Hazards 
Since the number of women in the workforce has been increasing substantially, maternal 
exposure to occupational hazards is a highly relevant and important factor to study. 
Unfortunately, little research has been undertaken to clearly conclude whether exposure to 




Studies by Cordier et al. (1992) and Lorente et al. (2000) found an association between the 
occurrence of CL/P with maternal occupations, such as janitors or cleaners. This is most 
likely because these mothers were exposed to solvents. Maternal exposure to solvents is 
linked to MCMs, some of which include urinary malformations, male genital malformations 
and OFC. Nurses, laboratory workers and hairdressers were also found to be affected 
(Garleantezec et al., 2009). Of the studies on this subject, one did not find a greater risk of 
CL/P with maternal occupational exposure to solvents (Shaw et al., 2003).  
2.5.2.7.2 Pesticides 
Pesticide exposure has also been investigated, and a systematic review and meta-analysis by 
Romitti et al. (2007) concluded that maternal exposure to pesticides has a small risk to the 
development of OFC. In 2014, Yang et al. studied the effect of agricultural pesticides on 
clefts and confirmed that there is a risk of OFC with maternal exposure to pesticides.  
2.5.2.7.3 Metals, Dust, Gases, and Fumes 
Not much evidence is available on maternal occupational exposure to metals, dust, gases 
and fumes. One study concluded that there is an association between metals and OFC (Hao 
et al., 2015). Spinder et al. (2017), on the other hand, found no significant association 
between the two. In addition, no association was found between maternal occupational 
exposure to gases and fumes and OFC (Spinder et al., 2017). However, the authors did find a 
causal relationship with maternal occupational exposure to dust.  
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2.5.2.8 Socioeconomic Status  
Womersley and Stone (1987) studied the effects of socioeconomic status in Greater 
Glasgow, Scotland and the risk of developing CL/P. They concluded that OFC were more 
common in socioeconomically deprived areas of the city, where residents had high 
unemployment rates and the majority were unskilled workers. Other epidemiological 
studies have reported similar findings: one in Wales (Durning et al., 2007) and another in 
California (Carmichael et al., 2009).  
2.6 Classification 
Several classification models for CL/P have been formulated over the years. Listed below are 
the models in chronological order: 
• Davies and Ritchie (1922) 
• Veau (1931) 
• Fogh-Andersen (1942) 
• Kernahan and Stark (1958) 
• Santiago (1969) 
• WHO (Bezroukov, 1979) 
• Kriens (1989) 
In the United Kingdom, the Kriens model, which utilises the LAHSAL code, has been chosen 
as the preferred classification method for clefts. The LAHSAL code, shown in Figure 3, is 
based on the striped Y diagrammatic classification. It splits the relevant parts of the oral 
cavity into six parts: 
• Right lip 
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• Right alveolus 
• Hard palate 
• Soft palate 
• Left alveolus 
• Left lip 
 
Figure 3 LAHASL code for classifying clefts. (Source: Kriens, 1989) 
The LAHSAL code is used with direct visualisation of the mouth and face. For example, the 
first character “L” on the left corresponds to the patient's right lip, and the last character “L” 
on the right corresponds to the patient's left lip. The code also indicates whether there is a 
complete cleft, written with an uppercase letter, or an incomplete cleft, written with a 
lowercase letter, or no cleft at all. 
2.7 Diagnosis 
Cleft lip with or without cleft palate can be detected with routine ultrasound examination 
(Clementi et al., 2000; Chmait et al., 2002). Chmait et al. (2002) showed that 100% of CL 
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cases and 90% of CP cases were identified with two-dimensional ultrasound with three-
dimensional ultrasound as an adjunct. Cases of CLP can be detected as early as 11 weeks in 
utero (Gullino et al., 2006). Submucous CP, on the other hand, is difficult to detect due to 
mucosa covering the cleft. It is diagnosed very late at a mean age of 4.9 years (Reiter et al., 
2011). These clefts are usually noticed by reported symptoms and physical examination. 
Common symptoms include hypernasal speech, Eustachian tube dysfunctions with 
conductive hearing loss, and nasal reflux when feeding (Reiter et al., 2011). Velopharyngeal 
impairment, failure of the soft palate to create a seal between the oral and nasal cavity, is 
diagnosed by at least one of the following diagnostic procedures: nasoendoscopy or 
videofluoroscopy (Nagarajan et al., 2009).  
The National Health Service (NHS) Foetal Anomaly Screening Programme (FASP) offers 
screening to all eligible pregnant women. The screening process consists of two scans. The 
first scan, which is done between weeks 10 to 14 of pregnancy, is preformed to detect 
Down’s syndrome, Edward’s syndrome and Patau’s syndrome. The second scan, which is 
recommended by the National Institute of Health and Care Excellence (NICE) guidelines, is 
to detect foetal anomalies and is performed between 18 weeks 0 days to 20 weeks 6 days of 
pregnancy.  







Conditions Detection Rate (%) 
Anencephaly 98% 
Open spina bifida 90% 
Cleft lip 75% 
Diaphragmatic hernia 60% 
Gastroschisis 98% 
Exomphalos 80% 
Serious cardiac anomalies: 
• Transposition of the Great Arteries (TGA) 
• Atrioventricular Septal Defect (AVSD) 
• Tetralogy of Fallot (TOF) 
• Hypoplastic Left Heart Syndrome (HLHS) 
50% 
Bilateral renal agenesis 84% 
Lethal skeletal dysplasia 60% 
Edward’s syndrome (Trisomy 18) 95%** 
Patau’s syndrome (Trisomy 13) 95%** 
Table 3 Conditions screened as a minimum in England. 
** Detections rates will be reviewed once sufficient data is received following 
implementation of screening as part of the combined screening strategy.  
(Source: NHS Foetal Anomaly Screening Programme Handbook, 2018) 
2.8 Treatment  
Orofacial cleft is a complex disorder that requires long term multidisciplinary care and early 
intervention. The multidisciplinary team usually consists of: 
• Ear, nose, and throat specialists 
• Paediatric dentists 
• Orthodontists 
• Oral and maxillofacial surgeons 






In the United Kingdom, cleft services have been based around a centralised service for the 
last two decades (Sandy, 2019). The cleft team aims to provide cleft patients and their 
families with the appropriate care immediately after diagnosis. This usually involves a 
tailored care plan to meet each affected child’s needs. A standard care plan timetable for 
CL/P patients is shown in Table 4.  
Age Intervention 
Birth to 6 weeks  Feeding assistance 
Support for parents 
Hearing tests 
Paediatric assessment 
3 to 6 months  CL surgery 
6 to 12 months  CP surgery 
18 months  Speech assessment   
3 years  Speech assessment   
5 years Speech assessment   
8 to 12 years Alveolar bone graft 
12 to 15 years Orthodontic treatment  
Monitoring jaw growth  
Table 4 Chronology of CL/P care plan. (Source: NHS Treatment: Cleft lip and palate, 2016). 
Orofacial clefts are associated with maxillary growth restriction. This is usually due to 
scarring as a result of the lip and palate repair surgeries performed early during childhood. 
Therefore, individuals with CL/P usually require orthognathic surgery when growth has 
ceased to correct the anteroposterior discrepancy in the maxilla and mandible. Dental 
anomalies are also commonly present in individuals with CL/P. These anomalies include 
hypodontia, either developmentally absent or extracted for bone grafting purposes, 
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microdontia, supernumeraries, fusion, ectopic eruptions, taurodontism, and anterior 
crossbites (Aizenbud et al., 2011). For this reason, orthodontic treatment is usually needed 
in CL/P patients. 
2.9 Hierarchy of Evidence 
Evidence-based practice is defined as “the integration of the best research evidence with 
clinical expertise, patient values and patient circumstances” (Straus et al., 2011). In other 
words, it is finding the evidence available and using it to make clinical decisions. Although 
experience and opinions play a role, the focus should be on evidence-based practice.   
Straus et al. (2011) have written up five steps to practice evidence-based medicine, namely:  
1. Formulating the right clinical question 
2. Finding the best evidence 
3. Critically appraising the evidence 
4. Integrating critical appraisal with clinical practice and the patient 
5. Evaluating effectiveness 
A hierarchy of evidence, illustrated in Figure 4, ranks studies according to the methodology 




Figure 4 Hierarchy of evidence. (Source: Guyatt et al., 1995) 
Randomised controlled trial are the gold standard for comparing different interventions and 
are the best in determining a causal relationship. This study design is used to minimise bias 
and reduce the risk of systematic errors. The factors that make this study design robust and 
able to provide strong evidence are (Sibbald and Roland, 1998): 
• Randomisation 
• Blinding  
• Groups are treated equally except for the intervention 
• Intention to treat analysis is applied 
Unfortunately, randomised controlled trials cannot be applied to every clinical situation due 
to ethical reasons. Other drawbacks include difficulty in randomisation or recruitment of 
subjects, and they are more expensive and time consuming to run than other study designs.  
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Systematic reviews and meta-analyses are usually the first studies to be searched when 
trying to answer a question of interest due to their high level of evidence. This is because 
they have been written based on a standard methodological process and have been 
critically appraised, as well. Being situated at the top of the pyramid means that very few 
articles are available to answer the question at hand, and therefore such reviews may well 
include articles of lower levels of evidence. 
2.10 Systematic Review Overview 
A systematic review is a collection of all current evidence on a specific topic, answering a 
clearly formulated research question through critical appraisal (Antman et al., 1992; Oxman 
and Guyatt, 1993). Systematic reviews provide healthcare workers with a summary of all 
relevant studies to date. Over 5000 systematics reviews are stored in the Cochrane 
Database of Systematic Reviews, which is part of the Cochrane Library (Cochrane, 1972). 
This open access electronic database is a great source of information for healthcare workers 
to make the best clinical decisions based on the most reliable evidence available. Many 
systematic reviews contain meta-analyses, which use statistical methods to summarise the 
results of individual studies (Glass, 1976).  
The key characteristics of a systematic review include (Higgins et al., 2017): 
• A clearly stated set of objectives with pre-defined eligibility criteria  
• An explicit, reproducible methodology 
• A systematic search that attempts to identify all relevant studies  
• An assessment of the validity of the findings of the included studies 
•  A systematic presentation and analysis of the findings of the included studies 
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Systematic reviews and meta-analyses are becoming increasingly important today in the 
field of healthcare. There is so much published information that most healthcare providers 
do not have the time nor the skills to read and analyse the information themselves. 
Systematic reviews and meta-analyses summarise all the information available and present 
it in a single paper. Systematic reviews are up to date, present important clinical practice 
guidelines, and provide justification for the need for further research on the topic at hand.   
2.11 Systematic Reviews on Medication During Pregnancy and CL/P 
To have an idea of the literature available on the effects of medication during pregnancy on 
CL/P, a comprehensive search was performed. The following electronic databases were 
searched: MEDLINE, EMBASE, and the Cochrane library, using the keywords “cleft”, 
“medicine”, and “systematic review”. Six systematic reviews were obtained: 
1. Veroniki et al., 2017. Comparative safety of anti-epileptic drugs during pregnancy: A 
systematic review and network meta-analysis of congenital malformations and 
prenatal outcomes. 
2. Alsaad et al., 2015. First trimester exposure to topiramate and the risk of oral clefts 
in the offspring: A systematic review and meta-analysis. 
3. Jentink et al., 2010. Intrauterine exposure to carbamazepine and specific congenital 
malformations: Systematic review and case-control study. 
4. Chi et al., 2015. Safety of topical corticosteroids in pregnancy (review).  
5. Goldberg et al., 2015. Exposure to nitrofurantoin during early pregnancy and 
congenital malformations: A systematic review and meta-analysis. 
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6. Murphy et al., 2013. The risk of congenital malformations, perinatal mortality and 
neonatal hospitalisation among pregnant women with asthma: A systematic review 
and meta-analysis 
The six systematic reviews are summarised in Table 5 and described in greater detail below. 
2.11.1 Anti-Epileptics 
Pregnant women with epilepsy are often prescribed anti-epileptic drugs (AED) to manage 
their symptoms. However, not much is known about the safety of periconceptional use of 
AED. Therefore, the aim of the systematic review by Veroniki et al. (2017) was to compare 
the risk of congenital malformations of infants exposed to AED in utero to those not 
exposed. MEDLINE, EMBASE, and Cochrane CENTRAL were searched. These studies 
compared mono- or poly-therapy AED exposed infants to infants not exposed to AED, and 
the primary outcome they investigated was the incidence of MCMs, including CL/P. From 
the 96 eligible studies they looked at, the authors concluded that monotherapies (e.g. 
ethosuximide, primidone, topiramate, phenobarbital, phenytoin and valproate) and 
polytherapies (e.g. phenobarbital plus phenytoin plus primidone, phenytoin plus primidone, 
carbamazepine plus phenobarbital, and carbamazepine plus valproate) were both 
associated with a higher rate of CL/P than the controls.  
2.11.1.1 Topiramate  
Topiramate (TPM), one of the newer AED, has been approved for the treatment of epilepsy. 
It is also used to treat migraines and sleep and psychiatric disorders, as well as acting as an 
appetite suppressor. While some studies have shown an increased risk of OFC, equally, 
other studies suggest the contrary. A meta-analysis was conducted on all studies reporting 
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mothers exposed to TPM during pregnancy (Alsaad et al., 2015). Six articles met the 
inclusion criteria and this study provided strong evidence that first trimester exposure to 
TPM is associated with a six-fold increased risk of OFC. This conclusion implies that women 
of child-bearing age taking TPM should be carefully monitored, and pregnant women should 
be informed about the teratogenic risks associated with this therapeutic agent. 
2.11.1.2 Carbamazepine 
Carbamazepine is one of the most common AED used among pregnant women in Europe. 
Several studies have evaluated the risk of MCMs associated with carbamazepine. However, 
because of the small sample size of each individual study, the statistical power was not 
sufficient to detect whether there was a risk of specific congenital malformations. 
Therefore, the aim of the systematic review by Jentink et al. (2010) was to identify the risk 
of specific malformations associated with first trimester exposure to carbamazepine. 
PubMed, EMBASE, Web of Science, and the EUROCAT Antiepileptic Study Database were 
searched. From the eight studies they included, the authors concluded that there is a 3.3% 
risk of congenital malformations, with a significantly lower risk of CL/P with carbamazepine 
monotherapies than with other AED, excluding valproic acid.  
2.11.2 Topical Corticosteroids 
Topical corticosteroids are the most commonly prescribed dermatological treatment. 
However, not much evidence is available about their safety when used during pregnancy. 
Chi et al. (2015) updated the 2009 systematic review on the safety of topical corticosteroids 
during pregnancy. MEDLINE, EMBASE, and LILACS were searched. Seven additional 
observational studies were added to the original seven making a total of 14 studies 
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investigated. They concluded that there is no association between maternal exposure to 
topical corticosteroids and OFC.  
2.11.3 Nitrofurantoin  
Urinary tract infections are one of the most common conditions that occur during 
pregnancy, and if not treated, may result in morbidity for both the mother and her foetus. 
Penicillin is the treatment of choice. However, because of the increasing resistance to 
penicillin, nitrofurantoin is the next commonly prescribed alternative. Unfortunately, the 
safety of nitrofurantoin use during pregnancy remains controversial. The recent systematic 
review by Goldberg et al. (2015) searched Medline and EMBASE and the authors included 
eight studies fitting the inclusion criteria. They concluded that there was no significant 
association between foetal exposure to nitrofurantoin during the first trimester of 
pregnancy and OFC. Therefore, it was concluded that nitrofurantoin can be safely used 
during pregnancy when resistance to penicillin is evident.  
2.11.4 Bronchodilators and Inhaled Corticosteroids 
Asthma is a common condition reported in pregnant women and is usually treated with 
bronchodilators or inhaled corticosteroids. The first systematic review and meta-analysis 
published on the effects of asthma during gestation was in 2011 (Murphy et al., 2011). Two 
years later, an updated meta-analysis was published focusing more on specific congenital 
malformations, including CL/P (Murphy et al., 2013). After extracting the data and analysing 
the results from sixteen studies, the authors concluded that asthma indeed was associated 
with a significantly increased risk of congenital malformations, specifically CL/P with an 
increased risk of 30%. Oddly, however, the use of bronchodilators and inhaled 
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corticosteroids were not the cause of the congenital malformations that resulted. Due to 
the limited number of studies available, the true association between maternal asthma and 
congenital malformations remains unclear. Maternal asthma has been associated with low 
birthweight and preterm delivery, which increases the risk of congenital malformations 
(Murphy et al., 2011). 
 
This current review of the literature has shown that no systematic analysis of the available 
evidence has to date been undertaken to assess the impact of foetal exposure to the 
maternal intake of antimicrobials, other than penicillin, on CLP. The aim of this study was 
therefore to systematically review the evidence from published studies on maternal 












Veroniki et al., 2017 MEDLINE 
EMBASE 
Cochrane 
AED Congenital malformations 96 AEDs are associated with CL/P 
Alsaad et al., 2015 MEDLINE 
EMBASE 
Web of Science 
TPM OFC 6 TPM is associated with OFC 
Jentink et al., 2010 PubMed 
EMBASE 
Web of Science 
Carbamazepine Congenital malformations 8 Carbamazepine is associated 
with lower risk for CL/P 




Topical corticosteroids Congenital malformations 14 Topical corticosteroids are not 
associated with OFC 
Goldberg et al., 2015 MEDLINE 
EMBASE 
Nitrofurantoin Congenital malformations 8 Nitrofurantoin is not associated 
with OFC 









16 Bronchodilators and inhaled 
corticosteroids were not 
associated with CL/P 
Table 5 Summary of systematic reviews on medication during pregnancy and CL/P.
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3.0 MATERIALS AND METHODS 
3.1 Overview 
A systematic review is a thorough and detailed critical appraisal of the literature extant on a 
specific topic answering a clearly focused question (Moher et al., 2007). Systematic reviews 
are considered to be the second best source of research evidence after a meta-analyses, and 
they are particularly important in evidence-based dentistry, as they are in other fields of 
medicine (Straus et al., 2011). A systematic review requires a protocol that defines the study 
aims, objectives and expected outcomes. The design of the study is clearly critical for the 
systematic review. 
3.2 Aim 
The aim of this systematic review is to investigate if there is any association between the 
occurrence of NSOFC and foetal exposure to macrolides, antifungals, and antivirals/ 
antiretrovirals in utero. 
3.3 Objectives 
• To identify all relevant studies published to date on the effect of in utero exposure to 
antimicrobials on NSOFC and to analyse the evidence. 
• To provide information for future studies seeking to investigate and clarify the risks 
of maternal intake of antimicrobials during pregnancy in relation to NSOFC.  
• To increase awareness among women of child-bearing age worldwide on the effects 
of antimicrobials on their unborn infant. 
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3.4 Null Hypothesis 
The null hypothesis states that maternal exposure to either macrolides, antifungals, or 
antivirals/ antiretrovirals has no effect on the development of NSOFC.  
3.5 Materials and Methods 
A systematic review comprises a methodology which searches the literature, identifies, and 
selects relevant studies, and appraises and synthesises the evidence. The methodology is 
specific, reproducible, and aims to minimise bias. After formulating a question and defining 
the aims and objectives of the review, it is important to define the inclusion and exclusion 
criteria to select relevant articles.   
3.5.1 Inclusion Criteria 
The inclusion criteria for this study were: 
• Infants with NSOFC 
• Mothers exposed to macrolides, antifungals, and/or antivirals/ antiretrovirals in 
utero 
3.5.2 Exclusion Criteria 
The exclusion criteria for this study were: 
• Foreign language studies  
• Syndromic OFC 





• Conference papers 
• Literature reviews 
• Case reports and case series 
A systematic review is more comprehensive than a simple literature review in that it may 
include both published and unpublished literature. The inclusion of unpublished literature, 
also known as “grey” literature, adds strength to a systematic review as it is often more 
current than other published literature and is less likely to have publication bias. Several 
preliminary attempts to identify grey literature proved fruitless and it was disappointing that 
even much of the other published work was unable to provide raw data for further analysis. 
3.5.3 Literature Search 
The literature search is the major component of any systematic review process. It is a 
complex process that requires searching different databases. Training to undertake this 
systematic review comprised a four-day short course in June 2018 “Systematic Reviews and 
Meta-Analysis”, held at the Department of Population Health Sciences in the Medical 
School, University of Bristol. Access to the literature and articles was available online and 
from the library in the University of Bristol.  Direct support was also available and freely 
given by the librarians.  
The following electronic databases were searched: MEDLINE, Embase, and the Cochrane 
Library using exploded MeSH headings and text words (Appendix A). To identify terms 
related to antimicrobial exposure, the following search terms were combined with OR:  
• antibiotic* or macrolide* or azithromycin* or clarithromycin* or erythromycin* or 
fidaxomicin* or telithromycin* 
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• antigungal* or fluconazole* or diflucan* or griseofulvin* or gris peg* or fulvicin pg* 
grifulvin v* or itraconazole* or sporanox* or ketoconazole* or nizarol* or 
terbinafine* or lamisil* 
• antiviral* or amantidine* or symmetrel* or rimantadine* or flumadine* or 
oseltamivir* or tamiflu* or zanamivir* or relenza* 
Relevant papers were identified by searching subject headings and keywords for “cleft lip”, 
“cleft palate”, and “orofacial cleft”. Both exposure and outcome searches were combined 
with AND, and the search was limited to human studies only.  
3.5.4 Screening 
When the search was completed, all titles and/or abstracts were screened. After the initial 
screening, many of the articles were rejected because of the defined initial inclusion and 
exclusion criteria. A full text of all the identified articles were then retrieved from the library 
e-journals and read in more detail. Fortunately, all articles were available online and there 
was no need to request an inter-library loan on behalf of the university. Papers that could 
not be excluded based on the initial review, were assessed by a second reviewer (NH), and 
any disputes were resolved by a third reviewer (AI). Duplicate articles from the different 
electronic databases were removed. Moreover, reference lists of included articles were 
hand searched for additional studies that were not identified in the initial search.  
3.5.5 Data Extraction 
Once all the relevant articles were identified, an electronic data extraction form was 
constructed to ensure that all relevant information was obtained from each of the studies 
included. The data extraction form that was used for this systematic review is a self-
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modified version of the data extraction template provided online in the Cochrane Public 
Health Group. The form includes details of study and participant characteristics, setting, 
results, etc. (Appendix B). Where results from a single study were reported in multiple 
publications, data was extracted from the latest published article with the longest time 
interval from the initial publication. 
3.5.6 Quality Assessment  
No one method exists to assess quality of a study as each has its own strengths and 
weaknesses (Rethans et al., 1996). However, the majority agree on two minimum 
requirements: 
• Selection of the appropriate study design to answer the research question 
• Assessing risk of bias 
Two resources used to assess the quality of studies included in this systematic review are 
the Critical Appraisal Skills Programme (CASP) (CASP, 2018) and the ROBINS-I risk of bias 
tool (Sterne et al., 2016). 
3.5.6.1 Critical Appraisal  
Sanderson et al. (2007) suggested a critical appraisal should include the following: 
• Appropriate study design selection 
• Appropriate selection of participants  
• Appropriate measurement of variables  
• Appropriate control of confounding factors 
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The online CASP was used to assess the quality of the studies included in this review, 
individually. The articles that were identified from the search were all observational studies, 
comprising of cohort and case control studies. A specific quality assessment checklist for the 
two different types of study designs were downloaded from CASP (Appendix C). 
3.5.6.2 Risk of Bias 
The Cochrane “Risk of Bias” tool was used to assess the level of bias in the systematic 
review. There are three tools that can be used: 
• RoB 2.0 tool (revised tool for risk of bias in randomised trials) 
• ROBINS-I tool (risk of bias in non-randomised studies of intervention) 
• robvis (visualisation tool for risk of bias assessments in a systematic review) 
As the articles included in this review were all non-randomised studies, the ROBINS-I tool 
was used to assess the risk of bias. There are seven domains to assess: 
1. Bias due to confounding 
2. Bias due to selection of participants 
3. Bias in classification of interventions 
4. Bias due to deviations from intended interventions 
5. Bias due to missing data 
6. Bias in measurement of outcomes 
7. Bias in selection of the reported result 





Low risk of bias The study is comparable to a well performed randomised trial. 
Moderate risk of bias The study is sound for a non-randomised study but is not 
comparable to a well performed randomised trial. 
Serious risk of bias The study has some important problems. 
Critical risk of bias The study is too problematic to provide any useful evidence.  
No information  No information on which to base a judgement about risk of bias. 
Table 6 Interpretation of domain-level and overall risk of bias judgements in ROBINS-I. 
(Source: Sterne et al., 2016) 
To produce the risk of bias figures, the data from ROBINS-I was uploaded on robvis 
(McGuinness, 2019). This web application creates two charts: 
• “Traffic light” plot of the domain-level judgements for each study 
• Weighted bar plot of the distribution of risk of bias judgements within each domain 
These charts are illustrated in Figures 5 and 6 (vide infra 4.4).  
3.5.7 Data Synthesis 
The data extracted from the literature can either be presented as a narrative review and/or 
a statistical review or meta-analysis. A meta-analysis usually includes numerical and 
graphical presentations of the data. If the studies included in a review are extremely 
heterogenous, it is difficult to present the data as a meta-analysis and summarising the data 
with a narrative approach is more appropriate. 
 The data in this review was collated and grouped according to: 
• Exposure (i.e. macrolides, antifungals, and antivirals/ antiretrovirals) 
• Outcome (i.e. CL/P, CL, CP, and CLP) 
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• Time of exposure in utero (i.e. periconceptional and entire pregnancy) 
3.5.8 Meta-Analysis 
The data collected in this study were summary statistics based on a binary response (e.g. 
presence or absence of a cleft). A random effects model was used for the meta-analysis to 
obtain summary estimates of the effect of antimicrobial (macrolides and antifungals), taken 
by the mother either periconceptually or during the entire pregnancy, on the odds of having 
a child with a cleft (either CL/P, CL, CP or CLP). Of the 17 papers identified in the review only 
eight provided sufficient data to be included in the meta-analysis. In order to be included 
the studies had to report the following: sample size, Odds Ratio (OR) (or the Adjusted Odds 
Ratio (AOR), which is an odds ratio adjusted for other predictors in the model, or Prevalence 
Odds Ratio (POR), which is the prevalence at a point in time), 95% confidence intervals (CI) 
of the OR (including AOR and POR), or provide sufficient statistics to enable these values to 
be calculated. There was insufficient data available on antivirals and antiretrovirals and 
these are described using a narrative synthesis of the relevant papers.   
A random effects model was used as the assumption was that each study was measuring a 
true, study specific effect, not necessarily from the same population, but different 
populations from around the world. The advantage of a random effects over a fixed effects 
models is that very large studies are not given undue weight to the exclusion of the smaller 
studies. 
The analysis was stratified by antimicrobial, cleft phenotype, and time of the antimicrobial 
exposure during pregnancy and is presented as forest plots. Bias was also assessed using 
contour enhanced funnel plots where contour lines aid the assessment of statistical 
significance of study estimates. 
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3.5.8.1 Forest Plots 
Forest plots are graphs used in meta-analyses to display the findings of the individual 
studies included in the systematic review as well as the overall summary of results to a 
particular outcome (Schriger et al., 2010). The results are usually weighted according to the 
statistical power of the study, and this is represented by a box. Studies with larger sample 
sizes and smaller CI, are indicated with a larger box and contribute greater to the pooled 
analysis. Whereas studies of lower power are indicated by a smaller box. A standard format 
of forest plots usually consists of two columns. The column on the left lists the studies, and 
the column on the right plots the measures of effect, such as the OR.  
3.5.8.2 Funnel Plots  
Introduced by Light and Pillemer in 1984, funnel plots are scatterplots of effect estimates 
plotted against the measure of study size, which is usually the standard error. They are 
commonly used in meta-analyses to detect publication and other types of biases. The effect 
estimates from smaller studies are scattered at the bottom of the pyramid and larger 
studies taper towards the top. A symmetrical funnel plot usually implies the absence of bias. 
However, asymmetry does not always indicate reporting bias but can also be a result of 
heterogeneity or simply by chance (Sterne et al., 2011). Funnel plots can be improved by the 
addition of contours of statistical significance, which facilitate interpretation of the funnel 
plot and determine whether the cause of asymmetry is likely due to publication bias or not 




4.1 Studies Included in the Systematic Review 
The search strategy yielded 165 potentially relevant papers for inclusion according to the 
MeSH headings and text words entered. After screening, only 25 papers were identified as 
meeting the inclusion criteria. Duplicates were removed and only 15 papers remained. The 
full-text articles were retrieved to assess eligibility. Of the 15 articles, three were excluded; 
two were excluded due to lack of data on cleft and the other was excluded because it was a 
review paper. Five additional studies were identified from searching the references of the 
12 remaining articles. Therefore, a total of 17 articles were included in the systematic 
review. The flow chart showing the study selection is presented in Appendix D.  
The 17 studies were published between 1946 and 2017 and were conducted across three 
continents. Countries involved in these studies included the United States of America, 
Canada, the United Kingdom, Sweden, Denmark, Hungary, Japan, and China. These articles 
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Crude POR 1.33 (95% CI 
0.55-3.20) 
Adjusted POR 1.24 (95% 
CI 0.51-3.00) 
Carter et al., 
2008 
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Table 7 Summary of included studies. 
ID: 17 HIV before 
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Antibiotics are one of the most commonly used medications during pregnancy. They are 
indicated to treat infections, which is crucial for the health and wellbeing of both the 
mother and the foetus. Macrolides are a class of antibiotics that inhibit protein synthesis in 
bacteria, affecting gram-positive cocci and intracellular pathogens, such as mycoplasma and 
chlamydia. They are mainly bacteriostatic, but at higher concentrations they may be 
bactericidal to some types of microorganisms. 
Macrolides accounted for five of the 17 studies included in this systematic review. 
Erythromycin, the most widely known macrolide and first to be discovered, was investigated 
in all five studies. Other macrolides, such as azithromycin, clarithromycin, and 
roxithromycin, were also assessed in two of these studies. All five observational studies 
concluded that erythromycin is not associated with an increased risk of OFC. 
4.1.1.1 Muanda et al., 2017 
This population-based cohort study aimed at investigating the association between specific 
antibiotics and MCMs. Using the Quebec pregnancy cohort, all pregnant women covered by 
the Quebec Public Prescription Drug Insurance from January 1998 to December 2009 were 
included in the study. Out of the 139,938 pregnancies included, 15,469 were exposed to 
antibiotics and 124,469 were not exposed. Macrolides were the second most frequently 
used antibiotics, accounting for 15% of the pregnancies. Confounding factors, such as 
sociodemographic variables, maternal chronic co-morbidities, endometriosis and maternal 
infections, measures of healthcare one year prior to pregnancy, year of delivery, and infant 
gender, were all accounted for. This population-based cohort study concluded that in utero 
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exposure to macrolides was associated with an increased risk of organ-specific MCMs in 
infants, specifically the digestive system, with a 46% increased risk. Erythromycin was 
associated with an increased risk of urinary system malformations. However, as stated by 
the authors, this could have been a result of chance or due to residual confounding. 
Macrolides were not associated with an increased risk of CP.  
4.1.1.2 Mølgaard-Nielsen and Hviid, 2011 
The aim of this nationwide cohort study was to investigate the risk of OFC among pregnant 
women exposed to antibiotics. The study included a total of 806,011 single live births in 
Denmark from January 1, 1996 to September 30, 2008, from which 945 had CL/P and 400 
had isolated CP. From the total, only 98,852 were exposed to antibiotics. Potential 
confounders were adjusted for including birth year, maternal sociodemographic variables, 
socioeconomic status, maternal smoking, maternal co-morbidities, and use of other 
maternal drugs. Mølgaard-Nielsen and Hviid concluded that maternal exposure to 
antibiotics, including erythromycin, roxithromycin, and azithromycin, early in pregnancy was 
not associated with an increased risk of CL/P or CP.  
4.1.1.3 Crider et al., 2009 
The National Birth Defects Prevention Study is an ongoing population-based case control 
study of birth defects across ten states in the United States of America. The aim of this case 
control study was to investigate the association between antibiotics taken during pregnancy 
and selected birth defects. The study comprised 13,155 case mothers who had an infant 
with at least one major birth defect and 4,941 control mothers from the same geographical 
region. The findings were reassuring in that erythromycin, which was the second most 
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widely reported antibacterial used during pregnancy in that population group, was not 
associated with many adverse birth defects, including OC. Only anencephaly and transverse 
limb deficiency were seen to be associated with periconceptional use of erythromycin.  
4.1.1.4 Källen et al., 2005 
This case control study aimed to study the effects of maternal erythromycin intake during 
early pregnancy. From the Swedish Medical Birth Registry, 677,028 infants born between 
July 1, 1995 and December 31, 2002, whose mothers were exposed to erythromycin, were 
included in the study. These cases were compared to 9,110 infants who were exposed to 
penicillin V during early pregnancy. Confounding factors taken into consideration included 
infant’s year of birth, maternal age, parity, maternal smoking, earlier miscarriages, and use 
of other drugs. Unlike the other studies, this study indicated a teratogenicity of 
erythromycin when taken early in pregnancy, causing an increased risk of developing any 
congenital malformation. The authors have suggested that this may be due to the adverse 
effects on the cardiovascular system. Erythromycin has been seen to inhibit a specific 
cardiac potassium current channel, which in turn affects the cardiac rhythm in embryos. In 
addition to cardiovascular malformations, the study also shows an association between 
erythromycin and pyloric stenosis. Unfortunately, the authors only briefly mention cleft in a 
table. Out of the 62 cases that presented with MCMs after exposure to erythromycin in 
early pregnancy, only two cases had CP.  
4.1.1.5 Czeizel et al., 1999 
The third population-based case control study included in this systematic review also aimed 
at studying the teratological effects of erythromycin. Cases and controls were derived from 
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the Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 
1996. The study consisted of 22,865 infants born with CAs, of which 113 were exposed to 
erythromycin, and 38,151 infants born without CAs, of which 172 were exposed to 
erythromycin. Mothers who were on other pregnancy supplements, such as vitamins, iron, 
and calcium derivatives, were excluded. The study showed no increased risk of CAs, 
including CL/P and CP, in babies exposed to erythromycin during the second and third 
months of pregnancy, which is a critical time during which CAs can develop in a foetus.   
4.1.2 Antifungals  
Antifungals, also known as antimycotics, are fungicidal or fungistatic drugs used to treat 
fungal infections. There are two types of antifungals: local (topical or vaginal) or systemic 
(oral or intravenous) and are classified as polyenes, azoles, allylamines, echinocandins, and 
miscellaneous antifungals. Some of the most common antifungals include clotrimazole, 
econazole, miconazole, terbinafine, fluconazole, ketoconazole, and amphotericin.  
Pregnant women are at great risk of developing vulvovaginal candidiasis, and topical azoles 
are the first line of treatment for these cases. The Food and Drug Administration (FDA) 
guidelines and the Centres for Disease Control and Prevention (CDC) recommendations 
suggest avoiding oral fluconazole for the treatment of vulvovaginal candidiasis in pregnancy. 
Despite these guidelines, fluconazole is still being prescribed today (Howley et al., 2016).  
This systematic review includes seven studies investigating antifungal medications, five of 
which provide data on in utero fluconazole exposure. Four of these studies concluded that 
there is no association between fluconazole and the development of CL/P. However, the 
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most current article states that there is a significant association between fluconazole use 
and CLP.   
4.1.2.1 Howley et al., 2016  
As fluconazole is commonly prescribed to treat vulvovaginal candidiasis, Howley et al. 
(2016) investigated the potential teratogenicity of fluconazole during the first trimester of 
pregnancy. This population-based case control study included all pregnancies with delivery 
dates between October 1, 1997 and December 31, 2011. Cases comprised 31,645 mothers 
who had infants with at least one major structural birth defect and 11,612 mothers who had 
infants without any birth defects. Of the 43,257 mothers analysed, 44 case mothers and six 
control mothers were exposed to fluconazole during the first trimester. This study showed a 
significant association between fluconazole and CLP (n = 6) and d-transposition of the great 
arteries (n = 3). This supports the CDC recommendations and the FDA guidelines, which 
suggest avoiding fluconazole for the treatment of vulvovaginal candidiasis during pregnancy. 
However, the findings should be interpreted with caution as the sample size for exposed 
cases was small.  
4.1.2.2 Mølgaard-Nielsen et al., 2013 
This population-based cohort study investigated the association between first trimester oral 
fluconazole and the risk of 15 major birth defects known to be associated with azole 
antifungals. All 976,300 live births from January 1, 1996 to March 31, 2011 from the Medical 
Birth Registry in Denmark were included in the study. Of these, 7,352 infants were exposed 
to fluconazole and 967,236 were not exposed. Reassuringly, the authors found no increased 
risk of 14 of the 15 birth defects, including CL/P and CP. Tetralogy of Fallot was the only 
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birth defect that was significantly associated with fluconazole exposure during early 
pregnancy.  
4.1.2.3 Carter et al., 2008 
The aim of this case-control study was to use data from the National Birth Defects 
Prevention Study from 1997 to 2003 to investigate the association between first trimester 
antifungal use and the risk of selected birth defects. The antifungal drugs included in this 
study are listed in Table 7, of which miconazole was the most commonly used. Miconazole, 
a topical azole, was mainly used to treat vulvovaginal candidiasis, except in three cases 
where it was used to treat ringworm, a fungal skin infection, and oral thrush. The cases 
totalled 7,047 babies, which included live births, still births ( 20 weeks or > 500 g), or 
elective terminations with birth defects. Controls, on the other hand, were 4,774 live births 
without any birth defects. Both cases and controls were exposed to antifungals during the 
first trimester. This study found no association with first trimester exposure to antifungals 
and most birth defects including CL/P. However, there was an increased risk for hypoplastic 
left heart syndrome.  
4.1.2.4 Nørgaard et al., 2008 
This was the third of four studies included in this systematic review that purely focused on 
examining fluconazole. Although fluconazole is commonly used to treat candidiasis, there is 
limited data available on its potential side effects. This population-based cohort study aimed 
to examine any association between first trimester fluconazole and the risks of congenital 
malformations. From the Danish Medical Registry, 171,532 mothers who had a live birth or 
stillbirth from January 1, 1973 were selected. Of these, 1,079 were case mothers exposed to 
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fluconazole during the first trimester, and there were 170,453 controls. Case mothers gave 
birth to 44 (4.1%) infants with congenital malformations and control mothers gave birth to 
6,152 (3.6%) infants with congenital malformations. The authors concluded that there is no 
increased risk of congenital malformations, one of which was CL/P, when exposed to 
fluconazole during the first trimester of pregnancy.  
4.1.2.5 Czeizel et al., 2003 
Czeizel et al. (1999) had earlier conducted a case control study investigating clotrimazole. 
Four years later, they conducted a similar study, this time on econazole, another topical 
azole antifungal. The aim was to assess the risks and benefits of vaginal econazole 
treatment during pregnancy. Cases, which included either live births or terminated 
pregnancies with isolated or multiple CAs, were selected from the Hungarian Congenital 
Abnormality Registry. Each case was matched according to sociodemographic variables with 
two live birth controls without any CAs. Of the 22,843 cases, 68 infants were exposed to 
econazole, and of the 38,151 controls, 122 were exposed to econazole. The matched case-
control pairs did not show evidence of teratogenicity associated with vaginal econazole 
when taken in low doses, including CL/P. 
4.1.2.6 Jick, 1999 
In this case control study, which aimed at evaluating the risks of maternal exposure to 
fluconazole during the first trimester, 234 exposed women were selected from the General 




1. 492 women exposed to topical azoles, including miconazole, ketoconazole, and 
econazole 
2. 88 women exposed to oral itraconazole 
3. 1,629 women not exposed to azoles during the first trimester of pregnancy 
Out of these four groups, there were only two cases of CL/P, one exposed to topical azole 
and the other not exposed to any azole. The authors concluded that there is no association 
between CAs and infants exposed to fluconazole during the first trimester.  
4.1.2.7 Czeizel et al., 1999 
This case control study was conducted to examine the teratogenic effects of clotrimazole 
during pregnancy. Infants with isolated and multiple CAs born between 1980 and 1992 were 
selected from the Hungarian Case-Control Surveillance of Congenital Abnormalities. The 
study included 18,515 cases and 32,804 controls of which 7.1% and 7.7% were exposed to 
clotrimazole, respectively. Potential confounding factors, such as maternal age, birth order, 
pregnancy complications, acute and chronic maternal disorders and use of other 
medications, were taken into consideration. The data presented did not show any 
association between clotrimazole exposure during pregnancy and multiple CAs, including 
the risk for CL/P and CP. However, there was evidence for a reduction in the prevalence of 
undescended testis.  
4.1.2.8 Hill et al., 1988 
Around 1988, evidence was available linking limb reduction defects to periconceptional 
intake of thalidomide and OC to anticonvulsants. However, there was limited evidence on 
the effects of other drugs on these two CAs. Therefore, this study was undertaken in the 
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United Kingdom to assess the effects of periconceptional drugs on limb reduction defects 
and OC. From the Office of Population Censuses and Surveys, all infants born with limb 
reduction defects and/or OC within one year from October 1, 1983 were included in the 
study. One hundred and fifteen mothers delivered infants with limb reduction defects and 
676 mothers had infants with OC. These cases were matched with an equal number of 
mothers who had the next normal infant in the same general practice. Like previous studies, 
this study confirmed that anticonvulsant drugs are significantly associated with an increased 
prevalence of OC. There was also a significant association between oral contraceptives and 
cleft development. However, there was no increased risk with antifungal exposure. 
Regarding limb reduction defects, there was no significant association with the listed 
exposures, and the authors disregarded this part of the study due to the small sample size in 
comparison to the OC cases.   
4.1.3 Antivirals/ Antiretrovirals 
Antiviral drugs are a class of antimicrobials used to treat viral infections. Most antivirals 
available on the market are designed to target the human immunodeficiency viruses (HIV), 
herpes viruses, hepatitis B and C viruses, and influenza A and B viruses. Unlike most 
antibiotics, antivirals do not destroy the pathogen, but rather they either inhibit their 
development before entering the cell or interfere with the processes that synthesize viral 
components after they have entered the cell. The latter approach is undertaken by specific 
antivirals known as antiretrovirals. Antiretrovirals are used to treat HIV and are usually used 
in combination. They include nucleoside reverse transcriptase inhibitors, non-nucleoside 
reverse transcriptase inhibitors and protease inhibitors. Research suggests that the use of 
antivirals and antiretrovirals during pregnancy is crucial to prevent further complications 
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and to prevent mother-to-child transmission of the virus. Therefore, the benefits outweigh 
the potential teratogenic risks.  
This systematic review included two studies on antivirals and two on antiretrovirals. 
However, because these four studies are heterogenous in the type of exposure, time of 
exposure, and cleft phenotype, an overall conclusion cannot be made. There was also 
insufficient data for this group of antimicrobials to be included in the meta-analysis. 
4.1.3.1 Minakami et al., 2014 
The Centers for Disease Control and Prevention (2019) states “Influenza (flu) is more likely 
to cause severe illness in pregnant women than in women of reproductive age who are not 
pregnant” (CDC, 2019). Therefore, it is crucial to treat infected, pregnant women with 
antivirals. However, with the development of resistance against non-teratogenic antivirals, 
the teratogenicity of other antivirals must be studied. This retrospective study aimed to 
evaluate pregnancy outcomes when exposed to laninamivir, a new antiviral medication on 
the market. Fifty members of the Japan Society of Obstetrics and Gynaecology and Japan 
Association of Obstetricians and Gynaecologists were asked to provide data on pregnant 
women who were prescribed laninamivir for the treatment of influenza during two time 
periods:  
1. October 1, 2011 to March 31, 2012  
2. October 1, 2012 to March 31, 2013 
Half of the physicians prescribed laninamivir to 112 pregnant women. Exposure was 
reported in three categories:  21 weeks, 22-36 weeks, and  37 weeks of gestation, and 
adverse events, such as miscarriages, preterm birth, congenital malformations, neonatal 
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and morbidity requiring treatment were evaluated. At  21 weeks of exposure, one mother 
had a miscarriage, nine had preterm births, and three had congenital malformations (CL, 
foot polydactyly, and farefoot varus deformity). Although there were no controls, this study 
suggests that there is no increased risk of adverse events when taking laninamivir during 
pregnancy.   
4.1.3.2 Liu et al., 2013 
This was the second paper included in this systematic review investigating antivirals. 
Telbivudine is the first line of treatment for chronic hepatitis B (CHB) during pregnancy. 
Recently, telbivudine has been administered to pregnant women during the third trimester 
to prevent mother-to-infant transmission of the virus. Although telbivudine is considered 
safe, there is limited information on the safety of telbivudine for the “entire” pregnancy. 
This cohort study aimed to assess this period of exposure. Between October 1, 2007 and 
May 31, 2012, all women intending to become pregnant or were < 12 weeks pregnant and 
had been diagnosed with CHB at the outpatient clinic in Beijing Ditan Hospital were included 
in the study. Eighty-six pregnant women exposed to telbivudine were followed up 
throughout the course of pregnancy as were their infants post-delivery. At the end of the 
follow-up period, 50 mothers delivered 52 full-term infants and 31 mothers were still 
pregnant. One mother had induced labour at 24 weeks of gestation to terminate her 
pregnancy for CLP. The other CA recorded was right ear accessories, which occurred in one 
infant. With an overall CA rate of 3.8%, the authors confirmed the safety of telbivudine in 
the treatment of CHB-infected pregnant mothers for the entire pregnancy.  
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4.1.3.3 Cartsos et al., 2012 
Antiretroviral drugs are also prescribed during pregnancy to prevent mother-to-child 
transmission of HIV. This cohort study specifically assessed the risk of CLP when pregnant 
women were exposed to antiretroviral prophylaxis. The FDA Adverse Events Reporting 
system database was searched, and a total of 26 CLP cases related to antiretroviral 
therapies were identified. The therapies were either monotherapies or combination 
therapies. This study was the first to find an association between antiretroviral drugs and 
the development of CLP. Listed below are the drugs from greatest (at the top) to least risk of 
an infant developing a cleft:  
• Efavirenz 
• Lamivudine 





4.1.3.4 Townsend et al., 2009 
This cohort study was the second antiretroviral study included in this systematic review. The 
aim of the study was to assess the association between in utero exposure to antiretroviral 
drugs and the development of CAs. From the National Study of HIV in Pregnancy and 
Childhood, 8,576 infants (live births or stillborn), born between 1990 and 2007 in the United 
Kingdom and Ireland, were included. Of the 8,242 infants that had information on CAs, only 
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232 infants had at least one CA. This resulted in an overall CA rate of 2.8%. Fourteen infants 
were not exposed to antiretrovirals, 53 were exposed following the first trimester, and 147 
were exposed following the second or third trimester. Regarding OFC, there were only 
seven infants with CL/P; five of which were exposed to antiretrovirals during the second or 
third trimester, one during the first trimester, and the other was not exposed at all. This 
study found no association with CAs and the type of antiretroviral exposure. Nor did they 
find an association with time of exposure. The authors concluded that in utero exposure to 
antiretrovirals is not associated with an increased risk to CAs.  
4.2 Variables Included in the Meta-Analysis 
Across the 17 studies included in this systematic review, there was a wide range of 
heterogeneity in terms of exposure, time of exposure, and outcome. In order to conduct a 
meta-analysis, these factors had to be grouped in such a way that the articles could be 
related quantitatively. 
4.2.1 Exposure 
This systematic review categorised the exposure into the following three groups:  
• Macrolides 
• Antifungals 
• Antivirals/ antiretrovirals 
However, for the meta-analysis, it was decided to exclude antivirals/ antiretrovirals as there 
was insufficient homogenous data available. The different subtypes of antimicrobial 
categories were also disregarded in the meta-analysis as their inclusion would in turn 
increase the heterogeneity in the analysis.  
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4.2.2 Time of Exposure 
Different in utero exposure times were assessed across the 17 papers, and they have been 
divided into two categories: 
• Periconceptional period of pregnancy 
• Entire pregnancy 
Periconceptional is defined as the period before conception to the end of the first trimester. 
Therefore, any study that mentioned “periconception*”, “first trimester”, “first month”, 
“second month”, or “third month” were grouped under the periconceptional period of 
pregnancy. The second category included studies that assessed the “fourth through ninth 
months” and “entire pregnancy”.  
4.2.3 Outcome 
This systematic review addressed NSOFC. The studies investigated the effects of 
antimicrobials on different cleft phenotypes, which included CL, CP, CL/P, and CLP. To 
simplify the meta-analysis, the outcome was divided into two groups: 
• CL/P 
• CP 
The CL/P group included CL, CLP, and CL/P. The CP group comprised CP alone. Data on OC as 
a broad term was available in three papers (Crider et al., 2009, Hill, 1988, and Mølgaard-
Nielsen et al., 2013). It was decided to excluded OC from the meta-analysis as it was not 
possible to categorise OC under either CL/P or CP.  
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4.3 Critical Appraisal  
As previously mentioned, the studies included in this review were individually appraised 
using the online CASP checklist. The quality assessment checklists for the case control and 
cohort studies are presented in Tables 8 and 9, respectively. Irrespective of the study 
design, the headings, “A”, “B”, and “C”, in the second row correspond to three questions: 
A. Are the results of the study valid? 
B. What are the results? 
C. Will the results help locally? 
The numbers in the third row are questions that help answer “A”, “B”, and “C”. The first 
column with a designated study number corresponds to the study IDs from Table 7. A “✓” 
shows that this part of the appraisal was done appropriately, whereas a “X” means it was 




Case Control Studies 
 A B C 
 1 2 3 4 5 6a 6b 7 8 9 10 11 
Study 1 ✓ ✓ ✓ ✓ X ✓ ✓ * * ✓ ✓ ✓ 
Study 2 ✓ ✓ ✓ ? ✓ ✓ ✓ * * ✓ ✓ X 
Study 5 ✓ ✓ ✓ ✓ ✓ ✓ ✓ * * ✓ ✓ ✓ 
Study 6 ✓ ✓ ✓ ✓ ✓ ✓ ✓ * * ✓ ✓ ✓ 
Study 7 ✓ ✓ ✓ ✓ X ✓ ✓ * * ✓ ✓ X 
Study 8 ✓ ✓ ✓ X ✓ ✓ X * * X ✓ ✓ 
Study 9 ✓ ✓ ✓ ✓ ✓ ? X * * X ✓ X 
Study 11 ✓ ✓ ✓ ✓ X ✓ ✓ * * ✓ ✓ ✓ 
Study 13 ✓ ✓ ✓ ✓ X ✓ ✓ * * ✓ ✓ ✓ 
Table 8 CASP of case control studies included in the review. 
A: Are the results of the study valid? 
1 – Did the study address a clearly focused issue? 
2 – Did the authors use an appropriate method to answer their 
question? 
3 – Were the cases recruited in an acceptable way? 
4 – Were the controls selected in an acceptable way? 
5 – Was the exposure measured to minimise bias? 
6a – Aside from the experimental intervention, were the groups treated equally? 
6b – Have the authors taken account the potential confounding factors in the design 
and/or in their analysis? 
B: What are the results? 
7 – How large was the treatment effect? 
8 – How precise was the estimate of the treatment effect? 
9 – Do you believe the results? 
C: Will the results help locally? 
10 – Can the results be applied to the local population? 
11 – Do the results of the study fit with other available evidence? 
  
✓ Yes 
X   No 
?   Unknown 





 A B C 
 1 2 3 4 5a 5b 6a 6b 7 8 9 10 11 12 
Study 3 ✓ ✓ ✓ ✓ ✓ ✓ ? ✓ * * ✓ ✓ X ✓ 
Study 4 ✓ ✓ ✓ ✓ X ✓ ✓ ✓ * * ✓ ✓ ✓ ✓ 
Study 10 ✓ ✓ ✓ ✓ X ✓ ✓ ✓ * * ✓ ✓ ✓ ✓ 
Study 12 ✓ ✓ ✓ ✓ X ✓ ? ✓ * * ✓ ✓ ✓ ✓ 
Study 14 ✓ ✓ ✓ ✓ X X ? ? * * X X X X 
Study 15 ✓ X X ✓ X X ✓ ✓ * * ✓ ✓ ? ✓ 
Study 16 ✓ ✓ ✓ ✓ X X ✓ ✓ * * ✓ ✓ ✓ ✓ 
Study 17 ✓ ✓ ✓ X X ✓ ✓ ? * * X ✓ ✓ ✓ 
Table 9 CASP of cohort studies included in the review. 
A: Are the results of the study valid? 
1 – Did the study address a clearly focused issue? 
2 – Was the cohort recruited in an acceptable way? 
3 – Was the exposure accurately measured to minimise bias? 
4 – Was the outcome accurately measured to minimise bias? 
5a – Have the authors identified all important confounding factors? 
5b – Have they taken account of the confounding factors in the design and/or analysis 
6a – Was the follow up of subjects complete enough? 
6b – Was the follow up of subjects long enough? 
B: What are the results? 
7 – What are the results of this study? 
8 – How precise are the results? 
9 – Do you believe the results? 
C: Will the results help locally? 
10 – Can the results be applied to the local population? 
11 – Do the results of this study fit with other available evidence? 
12 – What are the implications of this study for practice? 
 
4.4 Risk of Bias  
Figure 5 illustrates the risk of bias associated with each study included in the systematic 
review, as well as the overall risk of bias. Figure 6 shows the weighted bar plot of the 
✓ Yes 
X   No 
?   Unknown 
*   See Table 7 
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distribution of risk of bias judgements within each domain. Eight articles in the analysis were 
judged to have low to medium risk of bias and nine were judged to have serious risk. A 
major criticism of this tool is that it is completely subjective and even if one domain is 
judged as serious, the “overall” risk of bias is said to be at serious risk (Sterne et al., 2016). 
Therefore, these figures must be interpreted with caution.  
 
 
Figure 5 Traffic light plot. 






D1 – Bias due to confounding 
D2 – Bias due to selection of participants 
D3 – Bias in classification of interventions 
D4 – Bias due to deviations from intended interventions 
D5 – Bias due to missing data 
D6 – Bias in measurement of outcomes 







Figure 6 Weighted bar plot. 
4.5 Results of the Meta-Analysis 
Using the inclusion and exclusion criteria, 17 studies were included in the systematic review. 
Of the 17 studies, only 13 were initially included in the meta-analysis. The four articles 
excluded were those pertaining to antivirals/ antiretrovirals (Minakami et al., 2014; Liu et 
al., 2013; Cartsos et al., 2012; Townsend et al., 2009). However, the meta-analysis was 
limited to those measures that were either an “Odds Ratio” or “Prevalence Odds Ratio”. 
Therefore, we managed to extract data from eight of the 13 studies, which contained 
considerable clinical homogeneity (Crider et al., 2009; Muanda et al., 2017; Czeizel et al., 
1999; Czeizel et al., 2003; Howley et al., 2016; Mølgaard-Nielsen et al., 2013; Carter et al., 
2008; Czeizel et al., 1999).  
Bias due to confounding 
Bias due to selection of 
participants 
Bias in classification of 
interventions 
Bias due to deviations from 
intended interventions 
Bias due to missing data 
Bias in measurement of 
outcomes 
Bias in selection of the 
reported result 
Overall risk of bias 
Low risk Moderate risk Severe risk 
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A random effects meta-analysis was conducted to estimate the effect of macrolides and 
antifungals on the risk of developing a cleft. Antivrials/ antiretrovirals were not included in 
the meta-analysis as insufficient data could be obtained from the papers identified in the 
review. The data were analysed using Stata 16.1 (Stata Corp, College Station USA) statistics 
package. A random effects meta-analysis was used as it ensures less influence of larger 
studies on summary approximations. Odds Ratios and their upper and lower 95% 
confidence intervals (CI) where chosen as effect sizes (Hedges g) and plotted as Forest plots. 
The data were also analysed by subgrouping on cleft phenotype and timing of exposure 
during pregnancy (periconceptual and entire pregnancy). The heterogeneity between the 
studies was estimated using τ2 along with I2 and potential bias examined using contoured 
funnel plots with contours of statistical significance. If studies are missing in areas of low 
statistical significance, asymmetry may be due to publication bias, whereas when missing in 
areas of high statistical significance then publication bias is less likely to be the cause of the 
asymmetry (Palmer et al., 2008). 
It can be seen from the Forest plot (Figure 7), which includes the result of the studies 
looking at both macrolides and antifungals that the summary diamond for the OR crosses 
the line of no effect. In addition, the Hedge’s g, which is used to calculate the effect size and 
associated 95% CI, shows that the 95% CI includes zero (-0.1 (95% CI -0.17, 0.15)). Therefore, 
the analysis of the data from all the included studies would suggest that overall, there is no 
statistically significant effect of these two drugs on cleft development at the level of 
α = 0.05.  
When each drug type is considered separately, as in the Forest plot shown in Figure 9, once 
again in both cases it can be seen the summary diamond crosses the line of no effect and 
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the 95% CI for Hedge’s g in both cases include zero (Macrolides: 0.30 (95% CI -0.25, 0.31) 
(Antifungals: -0.30 (95% CI -0.22, 0.17)), confirming neither of the drug types included 
appear to lead to a statistically significant increase in the likelihood of the baby developing a 
cleft.  
When the Forest plot for individual cleft type is considered (Figure 11) it once again 
confirms no overall effect of drug type on cleft development with both summary diamonds 
crossing the line of no effect and the 95% CI of Hedge’s g including zero for CL/P, CL and CLP 
(CL/P, CL, CLP: -0.18 (95% CI -0.51, 0.15)), and similarly for CP only (CP: -0.01 (95% CI -0.17, 
0.15)).  
Similarly, when the time during which either macrolides or antifungals were used, namely 
periconceptual or over the entire pregnancy were considered, there was once again no 
statistically significant effect as shown on the Forest plot in Figure 13. Both summary 
diamonds cross the line of no effect and the 95% CI of Hedge’s g includes zero. For 
periconceptual it was 0.20 (95% CI -0.03, 0.42) and for the entire pregnancy it was -0.26 
(95% CI -0.51, 0.00). 
To perform a random effects meta-analysis an assumption is made that the data are 
homogenous. Measures of heterogeneity are τ2 and I2. If τ2 is <0.25 then the heterogeneity 
is considered low or “small” and I2 is given as a more subject percent score. In the Forest 
plot of all the studies combined (Figure 7) both values were 0.00, indicating the data was 
relatively homogenous. When the data was considered by drug it was also seen to be 
homogenous with the τ2 being 0.00 as was the I2 for antifungals, and it was still a very low 
0.7% for macrolides (Figure 9). In fact, the greatest value for heterogeneity was with cleft 
phenotype when with CL/P, CL, and CLP the I2 was still only 39.08%. 
 
 76 
Overall publication bias was assessed using contour enhanced funnel plots (Figures 8, 10, 12 
and 14). It can be seen in each case the results of the individual studies are symmetrically 





Figure 7 Forest plot illustrating the log (In) of the odds ratio (OR) and 95% confidence 
interval (CI) of all included studies in the meta-analysis (i.e. OR of 1 = chance of event or 
outcome = 0 on the Forest plot). Overall, the summary diamond crosses the line of no effect 
indicating no overall statistically significant effect of macrolides and antifungals on clefting. 












Figure 9 Forest plot of studies reporting the log (In) of the OR and 95% CI for cleft 
development when exposed to macrolides and antifungals (i.e. OR of 1 = chance of event or 
outcome = 0 on the Forest plot). The upper forest plot shows the OR of cleft when exposed 
to macrolides in utero (studies 1, 4, and 5), and the lower forest plot shows the OR of cleft 
when exposed to antifungals in utero (studies 6, 7, 10, 11, and 13). In both cases the 




Figure 10 Funnel plots illustrating the publication bias of studies 1, 4, and 5 (macrolides) and 




Figure 11 Forest plots of studies reporting the log (In) of the OR and 95% CI of CL/P and CP 
(i.e. OR of 1 = chance of event or outcome = 0 on the Forest plot). The upper forest plot 
shows the OR of CL/P, CL, and CLP (studies 1, 5, 6, 7, 11, and 13), and the lower forest plot 
shows the OR of CP (studies 1, 4, 5, 10, and 13). In both cases the diamond crosses the line 




Figure 12 Funnel plots illustrating the publication bias of studies 1, 5, 6, 7, 11, and 13 (CL/P) 




Figure 13 Forest plots reporting the log (In) of the OR and 95% CI of cleft at different time 
exposures (i.e. OR of 1 = chance of event or outcome = 0 on the Forest plot). The upper 
forest plot shows the OR of cleft when exposed to macrolides/antifungals during the 
periconceptual period of pregnancy (studies 1, 4, 5, 6, 7, 10, 11, and 13), and the lower 
forest plot shows the OR of cleft when exposed to macrolides/antifungals during the entire 




Figure 14 Funnel plots illustrating the publication bias of studies 1, 4, 5, 6, 7, 10, 11, and 13 





Reviews provide a summary of published literature on a specific topic. The two types of 
reviews in clinical research are systematic reviews and non-systematic or narrative reviews. 
Unlike systematic reviews, which follow a set of guidelines known as Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA), narrative reviews do not 
(Liberati et al., 2009). The lack of methodologies makes narrative reviews more prone to 
limitations, some of which include (Mulrow, 1987): 
• Subjectivity 
• Methods not transparent 
• Results not reproducible 
• No quantitative summary 
• Uncertainty  
The principal differences between narrative and systematic reviews are shown in Table 10. 
Conducting a systematic review is a time consuming and challenging task. Nevertheless, it is 
necessary in order to evaluate the efficiency of diagnostic and treatment interventions, as 
well as in this case, to help determine the outcome of therapeutic exposures (Collins and 
Fauser, 2005). As Sir Iain Chalmers, cofounder of the Cochrane Collaboration, states,  
“……. the results of a particular research study cannot be interpreted with any confidence 
unless they have been synthesised, systematically, with the results of all other relevant 
studies. 
… Science is meant to be cumulative, but researchers usually don’t cumulate scientifically…” 
(Chalmers et al., 2002) 
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 Narrative Reviews Systematic Reviews 
Main Features • Describe and appraise 
published articles with no clear 
method for selection of 
articles.  
• Well defined question. 
• Clearly defined criteria for 
selection of articles. 
• Explicit methodology for 
screening, extraction and 
synthesis of data.  
• Assess quality of studies.  
Uses • General debates, appraisal of 
previous studies and the 
current lack of knowledge. 
• Rationales for future research.  
• Speculate on new types of 
interventions available.  
• Identify and analyse the 
literature on a specific 
question to identify the basis 
of that knowledge. 
• Rational, assumptions and 
methods are open to external 
examination due to explicit 
methodology and 
comprehensive analyses.   
Limitations • The assumptions and processes 
are often not known.  
• Selection and evaluation biases 
are not known.  
• Not reproducible.  
• The scope is limited by the 
question, search terms, and 
the inclusion criteria. 
• The reader usually needs to 
come up with alternative 
questions that need to be 
answered. 
Table 10 The principal differences between narrative and systematic reviews. (Source: 
Ferrari, 2015) 
Bias is any process that interferes with producing results that deviate from the true values. 
Although systematic reviews aim at reducing bias and random error and employ an effective 
research methodology, systematic reviews still have several limitations, including the fact 
they are written retrospectively and so are prone to bias. This next section discusses the 
strengths and limitations of the current systematic review as a whole and of the individual 
included studies.  
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5.1 Strengths and Limitations of the Systematic Review and Meta-Analysis 
The main objective of this systematic review and meta-analysis, as with any, was to 
formulate a well-defined question and provide qualitative and quantitative analyses based 
on the evidence available in the literature. The true teratogenic effects of antimicrobials in 
the development of cleft is still not well understood. Therefore, the aim of the review was 
clearly stated as “to investigate if there is any association between the occurrence of NSOFC 
and foetal exposure to macrolides, antifungals, and antivirals/ antiretrovirals in utero ”. In 
addition to formulating a ‘focused’ question, the question also specifies the condition or 
diagnosis, the exposure, and the outcome, which are some of the criteria identified by 
Gregg et al. (2008) for assessing quality and strengths of a systematic review and meta-
analysis.  
This well-defined question set a foundation for the methodological process of the research. 
It had to be objective, reliable, and reproducible. The inclusion and exclusion criteria for the 
retrieval of studies were clearly listed, setting the boundaries for the review (vide infra 3.5.1 
and 3.5.2). Three electronic databases (MEDLINE, EMBASE, and Cochrane CENTRAL) were 
searched and reference lists of retrieved articles were hand searched, as well. To minimise 
human error, the articles were selected in duplicates and disagreements were resolved by a 
third reviewer. This extensive process of identifying and selecting relevant studies implies 
that publication bias is reduced. However, it was not completely avoided as only published 
articles in the English language were included in the search. It may also be argued that a 
limitation of this systematic review is the limited number of databases included in the 
search. However, MEDLINE and EMBASE are the two key international biomedical databases 




U.S. National Library of Medicine European, Elsevier 
Biomedicine and health Biomedicine, good for pharma research  
Citations from > 5,600 journals  
40 languages 
Citations from > 8,500 journals  
30 languages 
> 23 million records updated daily >30 million records updated daily  
(> 6 million records not on MEDLINE)  
80% with English abstracts 80% with English abstracts 
Searchable back to 1946 Searchable back to 1974 
Table 11 Key sources: MEDLINE and EMBASE. (Source: Dawson, June 2018) 
The PRISMA flow chart of the study selection was clearly presented, and all excluded studies 
were accounted for with the reason for exclusion (Moher et al., 1994) (Appendix D). A 
quality assessment checklist was obtained from the online CASP and was used to assess the 
quality of each included study (Tables 8 and 9). Risk of bias was also used to assess the level 
of bias in individual studies included in the review (Figures 5 and 6). Data was accumulated 
and analysed, and a meta-analysis was conducted. Due to heterogeneity across some of the 
articles, not all studies included in the review were included in the meta-analysis. 
The protocol of this systematic review and meta-analysis was not registered in the 
International Prospective Register of Systematic Reviews (PROSPERO), an online database of 
systematic reviews currently being undertaken. It is recommended to register the review 
prior to commencing the search to avoid any duplications. It is also useful for recording 
progress of the review. By not registering this review onto PROSPERO, the risk of bias 
increases due to a potential lack of transparency in the review process.   




• The aim was clearly stated. 
• The inclusion and exclusion criteria were 
stated. 
• Electronic databases (MEDLINE, EMBASE, 
and Cochrane CENTRAL) and reference 
lists of retrieved articles were searched. 
• Study selection and methodology was 
described. 
• Article selection was done in duplicates, 
and any disputes were resolved by a 
third reviewer. 
• List of included studies were provided. 
• Flow chart of study selection was 
provided. 
• Reason for exclusion of articles was 
given. 
• Quality assessment was done using CASP 
• Risk of bias was assessed (ROBINS-I). 
• Characteristics of individual studies were 
provided. 
• Meta-analysis was conducted. 
• Publication bias was assessed using 
Funnel Plots.  
• No conflicts of interest were reported.  
• Protocol was not registered on the 
PROSPERO database. 
• Only published articles were included. 
• Foreign language articles were excluded. 
• Data extraction was not done in 
duplicates.  
 
Table 12 Strengths and limitations of systematic review and meta-analysis. 
5.2 Strengths and Limitations of the Included Studies 
Critical appraisal is the process of judging the validity and quality of an article. Each study is 
critiqued according to the following (Derish and Annesley, 2011): 
• Methodology used to test the hypothesis 
• Limitations 
• Validity and quality of results obtained 
• Interpretation of the results 
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• Impact of the conclusion  
For this systematic review, each article was critically appraised using the online CASP 
according to the type of study design implemented (Appendix C). The CASP quality 
assessment checklist addresses three questions: 
1. Are the results of the study valid? 
2. What are the results? 
3. Will the results help locally? 
The discussion of the strengths and limitations of the studies included in the review were 
addressed according to these three questions and are as follows:  
5.2.1 Macrolides 
Are the results of the study valid? 
All five studies included in the review with macrolides as an exposure addressed a clearly 
focused issue, which included the population, exposure, and the outcome. The authors also 
used an appropriate study design to answer the question at hand.  
Selection bias may compromise the validity of the findings, and therefore assessing whether 
the cases and controls were selected in an appropriate manner is crucial. All cases were 
recruited in an acceptable way from national birth registries, which included all pregnancies. 
Excluding eligible cases from the study increases the risk of selection bias. For example, 
some studies excluded still born and/or induced abortions (Källén et al., 2005; Mølgaard-
Nielsen and Hviid, 2011; Muanda et al., 2017). This may have underestimated the true risk 
of cleft following maternal exposure to macrolides.  
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Two of the three case control studies included in this section of the review selected the 
controls randomly (Crider et al., 2009) and matched them to the cases (Czeizel et al., 1999), 
minimising selection bias. The controls were also representative of the population 
geographically, demographically, and temporally. The third case-control study selected the 
controls in a different manner. Källén et al. (2005) selected controls that were exposed to 
another type of antibiotic, penicillin V, which is a known non-teratogenic drug. Having cases 
and controls both exposed to antibiotics reduced the risk of confounding bias, as all 
participants had an underling infection that needed antibiotic treatment.  
In terms of confounding, all included studies in the review considered the potential 
confounding factors in the analysis and were clearly listed. Some of which included maternal 
age, ethnicity, parity, education, BMI, smoking, maternal disorders, periconceptional 
smoking and alcohol use, the consumption of folic acid, multivitamins, and other drugs 
during pregnancy. Although potential confounders have been adjusted for, residual or 
unmeasured confounding cannot be completely ruled out. For example, Muanda et al. 
(2017) did not account for maternal smoking, alcohol consumption, and folic acid intake, 
which have been shown to increase the risk of CLP.   
Recall bias is another factor to consider when critically appraising an article as it too may 
affect the findings. Mølgaard-Nielsen and Hviid (2011) and Muanda et al. (2017) measured 
the exposure objectively. Exposure data was taken from a public prescription drug insurance 
registry and from prescriptions and physician records, respectively. This minimised the risk 
of recall bias as well as detection bias. However, it may have increased the risk for 
information bias as not all mothers may have been compliant with taking the prescribed 
medication. The remaining studies obtained their exposure data subjectively by interviewing 
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the mothers either on the phone or by filling out a questionnaire. The time at which 
exposure data was collected varied from as early as 10-12 weeks of gestation, to as late as 
24 months postpartum. This may have increased the risk of recall and information bias as 
they may not fully or accurately recall the exact drug name and at what time during 
pregnancy it was taken.  
What are the results? 
Attempting to understand whether the results are believable relies on the level of bias. In 
observational studies, residual or unmeasured confounding factors are a key issue. Elevated 
OR may have occurred due to underlying maternal conditions and unmeasured confounding 
factors. This may result in overestimation of the outcome and a false association between 
the exposure and outcome. For example, maternal smoking increases the risk of respiratory 
infections leading to high intake of antibiotics. Some of the analyses investigating the 
association between macrolides and clefts were underpowered because of the small 
number of exposed cases (Crider et al., 2009; Czeizel et al., 1999).  
Will the results help locally? 
The results of the included studies in this review agree with the results of previously 
published studies in that there is no increased risk of cleft development when exposed to 
macrolides in utero. To be critical, the results should only be applied with confidence to 
mothers of the same geographical region the study was conducted in, as geography may 
play a major role in the prevalence of CLP (Mossey et al., 2011).  
5.2.2 Antifungals 
Are the results of the study valid? 
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The eight studies included in this section of the review all addressed a well-defined 
question. Cases were recruited in an acceptable way either from national birth registries or 
congenital malformation registries. One limitation of most of the studies is that they were 
only based on live births. By excluding terminated pregnancies, bias increases towards the 
null hypothesis because of the possibility of excluding pregnancies that may have been 
terminated due to the presence of a congenital malformation. Of the eight studies, two 
studies included stillbirths and/or elective terminations (Carter et al., 2008; Nørgaard et al., 
2008). Controls were also recruited with minimum bias and were representative of the 
defined population. Controls were either selected randomly from the same geographic area 
as the cases and around the same time, or they were matched according to gender, birth 
week, and geographic region.  
Overall, exposures were clearly defined and accurately measured with minimum bias. 
Studies included in this section of the review that measured the exposure objectively 
strengthened the study, and those that were measured subjectively weakened the study. 
Exposure data was extracted either from medical records, questionnaires and interviews, or 
a combination of both. By using questionnaires and interviewing mothers, the risk of recall 
and information bias increases (Howley et al., 2016; Carter et al., 2008; Czeizel et al., 1999). 
Interviewing mothers within 24 months of delivery increases the risks of mothers failing to 
recall the medication used, the dose, route of administration and duration of use. 
Antifungals are usually used for a short period of time of around seven to ten days and 
therefore, these types of details are easily forgotten. This potential under reporting of 
exposure may have contributed to the small number of exposed cases in these studies and 
therefore small OR. Reporting exposure objectively from medical records and prescription 
databases also comes with limitations. Firstly, we do not know whether these mothers took 
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the medication or not, and secondly, there is no data on ‘over the counter’ medication or 
medications prescribed by other practitioners (Hill et al., 1988; Jick, 1999; Mølgaard-Nielsen 
et al., 2013; Nørgaard et al., 2008). Czeizel et al. (2003) avoided these limitations by 
measuring exposure from medical records, the antenatal care logbook registry which 
records all prescribed drugs, and from questionnaires to the mothers. This allows for good 
triangulation of the data. 
Potential confounding factors were accounted for in the design and analysis of most of the 
studies in this section. However, unmeasured confounding is always a risk for false 
association between exposure and outcome. Was the development of a cleft due to the 
fungal infection itself, or was it due to the antifungal medication used to treat the infection 
that was the cause? This is referred to as indication bias. Maternal illness, a potential 
confounding factor, was not accounted for in the study by Mølgaard-Nielsen et al. (2013) as 
the registry they recruited their cohort from did not include this important information. Two 
of the eight studies did not state whether they had accounted for confounding factors (Hill 
et al., 1988; Jick, 1999). They may have not accounted for smoking, which is known to be 
associated with cleft development, or they may have not taken older maternal age into 
consideration, which is also linked with an increased risk of cleft.  
What are the results? 
Across the studies included in this review, the authors found no significantly increased risk 
of CLP when exposed to fluconazole in utero. These results were consistent with results of 
previous studies. However, the small number of exposed infants in the birth defect groups, 
including CLP, made it challenging to calculate a risk estimate. It may also be worthwhile to 
state that measuring exposure a month before pregnancy may have biased the estimates 
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towards the null hypothesis, as the embryo may not have developed during that time. The 
study by Howley et al. (2016) was the only study that found an increased risk of CLP with 
infants exposed to fluconazole periconceptionally. This association has not been reported in 
previous observational studies. Since there was no data on dose, the results may have been 
impacted by including high dose users into the cohort. As with the remaining studies, which 
found no evident association with CLP and topical econazole (Czeizel et al., 2003) or 
clotrimazole (Czeizel et al., 1999), no definite conclusion can be made as they were single 
case control studies assessing different antifungal medications.  
Will the results help locally? 
The results are reassuring. However, although the current studies show no increased risk of 
congenital malformations when exposed to antifungal medication during the critical period 
of pregnancy, the authors suggested larger cohorts of exposed pregnant women are needed 
to rule out the true association between fluconazole during early pregnancy and specific 
birth defects, such as CLP. A recent publication from the United States of America examined 
nearly two million pregnancies of which 38,000 were exposed to oral fluconazole in the first 
trimester (Zhu et al., 2020). This was not associated with OC but there was an association 
with musculoskeletal malformations which corresponded to a small adjusted risk difference 
of about 12 incidents per 10,000 exposed pregnancies overall.  
5.2.3 Antivirals/ Antiretrovirals  
Are the results of the study valid? 
This section of the review included four studies, all of which had clearly stated aims and 
objectives with the appropriate study design to tackle the question posed. However, 
because they were retrospectives studies, they are most likely at risk of bias. The cohorts 
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were recruited in an acceptable way and were representative of the targeted population. 
They were recruited from the FDA’s Adverse Events Reporting System database (Cartsos et 
al., 2012), the National Study of HIV in Pregnancy and Childhood (Townsend et al., 2009), 
and from outpatient clinics of the Beijing Ditan Hospital (Liu et al., 2013). However, the 
study conducted by Minakami et al. (2014) was prone to recall and selection bias. Physicians 
were asked to provide information on all women who they prescribed laninamivir to during 
pregnancy. Only half of the physicians participated in the study. This selective participation 
may have been affected by either a positive or adverse experience with the drug in 
question. Having not included any controls may be a limitation of these four observational 
studies, as well. However, risks were compared to that of the general population, and it was 
thought to be adequate for the analysis.  
The aetiology of CLP is multifactorial, i.e. both genetic and environmental factors play a role. 
Therefore, unaccounted confounding factors may overestimate the risks and result in false 
associations between the exposure and the outcome. Mothers with HIV have characteristic 
lifestyles that make them more prone to delivering infants with congenital malformations, 
and therefore the results and subsequent conclusions made by the authors must be 
interpreted with caution (Cartsos et al., 2012; Townsend et al., 2009).  
What are the results? 
Sample size has a significant impact on the interpretation of results. Having a small cohort to 
study may underestimate the association between exposure and outcome. For example, 
Minakami et al. (2014) recruited only 112 pregnant women of whom three gave birth to 
infants with congenital malformations, only one of which was CL. Although the results were 
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inconclusive, they do provide some level of reassurance for mothers being treated with 
laninamivir during pregnancy.  
Confidence intervals are another factor to assess when interpreting results of studies. 
Having a wide CI is one limitation of a study and is usually associated with a small sample 
size. This was the case with the study by Cartsos et al. (2012), which had the widest CI 
ranging from 85.89 to 447.32 for efavirenz as the exposure.  
Will the results help locally? 
One author concluded that there was a potential association between in utero antiretroviral 
use and cleft (Cartsos et al. 2012), whilst the other concluded there was no such association 
(Townsend et al., 2009). However, with the limited evidence available, the vast 
heterogeneity that exists between studies, and the limitations presented above, further 
research is required to reach a valid conclusion on the safety of antiretroviral drugs taken 
periconceptually. With respect to antivirals, the authors concluded that there was no 
increased risk of cleft development with their use during pregnancy. However, due to the 
small sample size and wide CIs, the results should be interpreted with caution (Cartsos et al. 
2012).   
In summary, the strengths of the included studies were as follows: 
• Addressed a well-defined question 
• Cases and controls recruited in an acceptable way 
• Exposure measured to minimise bias 
• Potential confounders accounted for 
• Believable and applicable results 
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The limitations of the included studies were: 
• Biases (e.g. selection, recall, information, confounding and publication bias) 
• Lack of assessment of these biases 
• Lack of causality  
• Heterogeneity 
5.3 Recently Published Systematic Reviews and Meta-Analyses  
To round off this review, the electronic databases (MEDLINE, EMBASE, and Cochrane library) 
were searched for the latest published systematic reviews and meta-analyses on the 
adverse effects of macrolides, antifungals, and antivirals/ antiretrovirals when taken during 
pregnancy. Four relevant papers were retrieved. They were published in the year 2019 and 
2020.  
1. Wu et al., 2020. Efficacy and safety of antiviral therapy for HBV in different 
trimesters of pregnancy: Systematic review and meta-analysis. 
2. Liu et al., 2019. Foetal outcome after maternal exposure to oral antifungal agents 
during pregnancy: A systematic review and meta-analysis.  
3. Zhang et al., 2019. The safety of oral fluconazole during the first trimester of 
pregnancy: A systematic review and meta-analysis.  
4. Fan et al., 2019. Associations between use of macrolide antibiotics during pregnancy 
and adverse child outcomes: A systematic review and meta-analysis.  
5.3.1 Wu et al., 2020 
Several antiviral medications, such as lamivudine, telbivudine, and tenofovir have been 
approved by the FDA and have been shown to be effective and safe in preventing mother to 
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child transmission of HBV. However, there is no current evidence on the most effective and 
safe time of administering the antiviral therapy during pregnancy. Therefore, the aims and 
objectives of this systematic review were to identify the most effective time to start antiviral 
therapy (early-middle pregnancy or late pregnancy) and to assess the foetal outcomes at 
different gestational intervals. PubMed, EMBASE, Web of Science, and Cochrane databases 
were searched for studies that assess the efficacy and safety of antiviral therapy during 
pregnancy up to July 1, 2019. Three randomised and 32 nonrandomised controlled trials 
were included in the review. The meta-analysis confirmed that administration of antiviral 
therapy prior to week 28 of gestation was associated with a lower risk for mother to child 
transmission of HBV than when administered later in pregnancy. There were no significant 
differences in the adverse effects of mothers and infants according to the time of 
administration of the antiviral. Unfortunately, no data was available on whether the type 
and time of administration of the antiviral influenced the development of CLP.  
5.3.2 Liu et al., 2019 
Vulvovaginal candidiasis occurs commonly during pregnancy and topical antifungals are 
usually prescribed. However, when topical antifungals fail, oral antifungals are prescribed. 
Since the foetal safety of oral antifungals remains debatable, this systematic review and 
meta-analysis aimed to investigate this dilemma. PubMed, EMBASE, and Cochrane Central 
Register of Controlled Trials (CENTRAL) were searched up to October 31, 2018. Nine studies 
matched the inclusion and exclusion criteria. Eight were cohort studies and the other was a 
case control study. The authors concluded that in utero exposure to fluconazole or 
itraconazole is not associated with an increased risk of birth defects in general. However, it 
is associated with an increased risk of specific birth defects. For example, oral fluconazole 
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increases the risk of limb and congenital heart defects, and oral itraconazole increases the 
risk of eye defects. Regarding CLP, only one case control study by Howley et al. (2016) found 
a significant association with fluconazole exposure during the first trimester as described in 
the current review.  
5.3.3 Zhang et al., 2019 
This was another systematic review and meta-analysis investigating the safety of oral 
fluconazole during the first trimester of pregnancy and published less than two months 
before the systematic review by Liu et al. (2019). PubMed, MEDLINE, EMBASE, Cochrane 
Library, ClinicalTrials.gov, and the metaRegister of Controlled Trials were searched up to 
April 2019. Six cohort studies and one case control study fitted the inclusion and exclusion 
criteria. The results suggested that oral fluconazole use during the first trimester is 
associated with spontaneous abortions and congenital heart defects. There was no mention 
of cleft as an adverse foetal outcome in this review. 
5.3.4 Fan et al., 2019 
Being the most used group of antibiotics worldwide, it is crucial to understand the potential 
adverse effects of macrolides when taken during pregnancy. As the current evidence is 
inconsistent, this systematic review and meta-analysis was conducted to investigate the 
association between in utero macrolide exposure and the adverse effects on both the foetus 
and the infant. Electronic databases were searched up to February 15, 2018. These included 
PubMed, EMBASE, Cochrane Library, Conference Proceeding Citation Index-Science, and 
ClinicalTrials.gov. Nineteen studies were included in the review: ten observational studies 
and nine randomised controlled trials. The study showed an increased risk of miscarriage 
when pregnant mothers were exposed to macrolides. However, its association with cerebral 
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palsy, epilepsy, and gastrointestinal malformations was inconsistent. Moreover, there was 
insufficient evidence regarding other congenital malformations, including CLP, to conclude 





Interpreting, analysing, and critically appraising the current research was a challenging task. 
Studies investigating the efficacy and safety of drugs are usually associated with ethical 
precautions. Hence, all the studies that were included in this systematic review and meta-
analysis were observational studies rather than randomised controlled trials and comprised 
both cohort and case control studies. Since most of the studies were retrospective in design, 
causal relationships are impossible to determine and only associations between exposure 
and outcome can be deduced. Therefore, the intention of this research was to 
systematically review all relevant published studies up to April 30, 2019, and to investigate 
any association between maternal exposure to antimicrobials (macrolides, antifungals, and 
antivirals/ antiretrovirals) and the development of NSOFC.  
The review and its pooled analysis showed no overall increased risk of NSOFC associated 
with in utero exposure of macrolides, antifungals, and antivirals/ antiretrovirals. On this 
basis, the null hypothesis can be accepted. There was also very little effect of time of 
exposure on the risk of an adverse outcome. Reassuringly, our review supports the 
published literature on the safety of erythromycin and fluconazole in low therapeutic doses, 
the most widely used macrolide and antifungal respectively, among pregnant women. With 
the antivirals and antiretrovirals, no overall conclusion can be reached as the data was 
limited and heterogenous, and so could not be included in the meta-analysis.   
However, it can be argued that the overall results provide a degree of reassurance, in that 
there were very few increases in the OR associated with mothers who were exposed to the 
antimicrobials in the included studies. This may have been due to limiting factors, such as 
indication for use or simply by chance. Although the risk may have been small, physicians 
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should consider prescribing safer alternative medications to treat the maternal infection 
wherever possible e.g. penicillin V rather than a macrolide. If not, it is imperative that 
pregnant mothers are aware of the potential adverse risks associated with using these 
antimicrobials during their pregnancy. Mothers exposed to macrolides, antifungals, and 
antivirals/ antiretrovirals should also be educated about undergoing a routine anomaly scan 
for early detection of CLP. Moreover, healthcare workers, including practitioners and 




7.0 FUTURE WORK  
This systematic review and meta-analysis has hopefully set a foundation for future studies 
to clarify the true association between maternal intake of macrolides, antifungals, and 
antivirals/ antiretrovirals and the development of NSOFC in children. Given the 
multifactorial aetiology of CLP, further investigations are recommended with larger 
numbers of mothers recruited and with a greater emphasis on CLP as the main adverse 
foetal outcome in the study. This knowledge will increase awareness of the potential risks of 
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Appendix A – Electronic Search Strategy 
Macrolides  
Search MEDLINE Embase 
1. (“cleft lip” or “cleft lips” or “cleft palate” or “cleft palates” or 
“orofacial cleft” or “orofacial clefts”).mp. 
28258 28519 
2. pregnan*.mp. 966816 833820 
3. 1 AND 2 3534 3895 
4. (antibiotic* or macrolide* or azithromycin* or clarithromycin* 
or erythromycin* or fidaxomicin* or telithromycin*).mp. 
391031 757387 
5. 3 AND 4 13 104 
 
Antifungals  
Search MEDLINE Embase 
1. (“cleft lip” or “cleft lips” or “cleft palate” or “cleft palates” or 
“orofacial cleft” or “orofacial clefts”).mp. 
28258 28519 
2. pregnan*.mp. 966816 833820 
3. 1 AND 2 3534 3895 
4. (antigungal* or fluconazole* or diflucan* or griseofulvin* or gris 
peg* or fulvicin pg* grifulvin v* or itraconazole* or sporanox* or 
ketoconazole* or nizarol* or terbinafine* or lamisil*).mp. 
31131 158453 







Search MEDLINE Embase 
1. (“cleft lip” or “cleft lips” or “cleft palate” or “cleft palates” or 
“orofacial cleft” or “orofacial clefts”).mp. 
28258 28519 
2. pregnan*.mp. 966816 833820 
3. 1 AND 2 3534 3895 
4. (antiviral* or amantidine* or symmetrel* or rimantadine* or 
flumadine* or oseltamivir* or tamiflu* or zanamivir* or 
relenza*).mp. 
127950 168787 





Appendix B – Data Extraction Form 
1. GENERAL INFORMATION 
                
Name/ID of data extractor  
Date data extraction completed 
(dd/mm/yyyy) 
 
Title   
First author  
Year of publication  
Journal published in   
Publication type 
(e.g. journal article, abstract, book 
chapter, etc.) 
 
Country of study  
Study funding source 
(including role of funders) 
 
 
2. STUDY ELIGIBILITY 
 
Type of study (e.g. case control, 
cohort, etc.) 
  
Setting   
Participants   
Include/Exclude    
 
3. STUDY DETAILS 
 
Enrolment and follow-up period 
(start and end date of study) 
  
Length of follow-up   









4. METHODS  
 
Method/s of recruitment of 
participants 
  
Inclusion criteria   
Exclusion criteria   
Exposure   
Representativeness (is the 
sample representative of the 
target population) 
  
Sample size calculation (what 
assumptions were made?) 
  
Randomisation    
Unit of analysis  
(e.g. by individuals, health 
professional, practice, hospital, 
community) 
  
Statistical methods used  





Number of participants    
Number allocated to each 
intervention group 
  
Were participants who entered 
the study adequately accounted 
for? 
  
Percentage of participants who 
completed the study 
  




Number of participants with 
missing information 
  
Age (median, mean, range)       
Sex   
Race/Ethnicity   
Other sociodemographic factors 
(e.g. educational level, literacy 










6. OUTCOMES  
 
Comparison   
Outcome    
Time points measured 
(specify whether from start or 
end of intervention) 
  
Person measuring/ reporting   
Blinding   
Unit of measurement  
(if relevant) 
  
Scales: upper and lower limits  
(indicate whether high or low 
score is good) 
  
Imputation of missing data 
(e.g. assumptions made for ITT 
analysis) 
  
Assumed risk estimate 
(e.g. baseline or population risk 
noted in Background) 
  
Outcomes specific to CLP   
 
7. APPLICABILITY  
 
Have important populations 
been excluded from the study?  
(consider disadvantaged 
populations, and possible 
differences in the intervention 
effect) Yes/No/Unclear 
 
Is the intervention likely to be 
aimed at disadvantaged 
groups?  
(e.g. lower socioeconomic 
groups) Yes/No/Unclear 
 
Does the study directly address 
the review question? 
(any issues of partial or indirect 
applicability) Yes/No/Unclear 
 
Key conclusions of study 
authors 
 







Appendix C – CASP Quality Assessment Checklist 
Cohort 
Section A: Are the results of the study valid? 
1. Did the study address a clearly focused issue? 
 Yes  
 Can’t Tell 
 No 
HINT: A question can be ‘focused’ in terms of 
• The population studied 
• The risk factors studied 
• Is it clear whether the study tried to detect a beneficial or harmful effect? 
• The outcomes considered 
2. Was the cohort recruited in an acceptable way? 
 Yes  
 Can’t Tell 
 No 
HINT: Look for selection bias which might compromise the generalisability of the findings: 
• Was the cohort representative of a defined population? 
• Was there something special about the cohort? 
• Was everybody included who should have been? 
 
Is it worth continuing? 
 
3. Was the exposure accurately measured to minimise bias? 
 Yes  
 Can’t Tell 
 No  
HINT: Look for measurement or classification bias: 
• Did they use subjective or objective measurements? 




• Were all the subjects classified into exposure groups using the same procedure? 
4. Was the outcome accurately measured to minimise bias? 
 Yes  
 Can’t Tell 
 No  
HINT: Look for measurement or classification bias: 
• Did they use subjective or objective measurements? 
• Do the measurements truly reflect what you want them to (have they been 
validated)? 
• Has a reliable system been established for detecting all the cases (for measuring 
disease occurrence)? 
• Were the measurement methods similar in the different groups? 
• Were the subjects and/or the outcome assessor blinded to exposure (does this 
matter)? 
5. (a) Have the authors identified all important confounding factors? 
 Yes  
 Can’t Tell 
 No  
HINT: 
• List the ones you think might be important, and ones the author missed 
5. (b) Have they taken account of the confounding factors in the design and/or analysis? 
 Yes  
 Can’t Tell 
 No  
HINT: 
• Look for restriction in design, and techniques e.g. modelling, stratified-, regression-, 
or sensitivity analysis to correct, control or adjust for confounding factors 
6. (a) Was the follow up of subjects complete enough? 
 Yes  





• The good or bad effects should have had long enough to reveal themselves 
• The persons that are lost to follow-up may have different outcomes than those 
available for assessment 
• In an open or dynamic cohort, was there anything special about the outcome of the 
people leaving, or the exposure of the people entering the cohort? 
6. (b) Was the follow up of subjects long enough? 
 Yes  
 Can’t Tell 
 No 
 
Section B: What are the results? 
7. What are the results of this study? 
HINT: Consider 
• What are the bottom line results? 
• Have they reported the rate or the proportion between the exposed/unexposed, the 
ratio/rate difference? 
• How strong is the association between exposure and outcome (RR)? 
• What is the absolute risk reduction (ARR)? 
8. How precise are the results? 
HINT: 
• Look for the range of the confidence intervals, if given 
9. Do you believe the results?  
 Yes  
 Can’t Tell 
 No 
HINT: Consider 
• Big effect is hard to ignore 
• Can it be due to bias, chance or confounding? 
• Are the design and methods of this study sufficiently flawed to make the results 
unreliable? 






Section C: Will the results help locally? 
10. Can the results be applied to the local population? 
 Yes  
 Can’t Tell 
 No 
HINT: Consider whether 
• A cohort study was the appropriate method to answer this question 
• The subjects covered in this study could be sufficiently different from your 
population to cause concern 
• Your local setting is likely to differ much from that of the study 
• You can quantify the local benefits and harms 
11. Do the results of this study fit with other available evidence? 
 Yes  
 Can’t Tell 
 No 
12. What are the implications of this study for practice? 
 Yes  
 Can’t Tell 
 No 
HINT: Consider 
• One observational study rarely provides sufficiently robust evidence to recommend 
changes 
• To clinical practice or within health policy decision making 
• For certain questions, observational studies provide the only evidence 
• Recommendations from observational studies are always stronger when supported 






Section A: Are the results of the study valid? 
1. Did the study address a clearly focused issue? 
 Yes  
 Can’t Tell 
 No 
HINT: An issue can be ‘focused’ In terms of  
• The population studied 
• Whether the study tried to detect a beneficial or harmful effect the risk factors 
studied 
2. Did the authors use an appropriate method to answer their question? 
 Yes  
 Can’t Tell 
 No 
HINT: Consider  
• Is a case control study an appropriate way of answering the question under the 
circumstances? 
• Did it address the study question? 
 
Is it worth continuing? 
 
3. Were the cases recruited in an acceptable way? 
 Yes  
 Can’t Tell 
 No  
HINT: We are looking for selection bias which might compromise validity of the findings 
• Are the cases defined precisely? 
• Were the cases representative of the defined population (geographically and/or 
temporally)? 
• Was there an established reliable system for selecting all the cases? 
• Are they incident or prevalent?  
• Is there something special about the cases? 
• Is the time frame of the study relevant to disease/exposure?  
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• Was there a sufficient number of cases selected? 
• Was there a power calculation? 
4. Were the controls selected in an acceptable way? 
 Yes  
 Can’t Tell 
 No  
HINT: We are looking for selection bias which might compromise the generalisability of the 
findings  
• Were the controls representative of the defined population (geographically and/or 
temporally)? 
• Was there something special about the controls?  
• Was the non-response high, could non-respondents be different in any way?  
• Are they matched, population based or randomly selected?  
• Was there a sufficient number of controls selected?  
5. Was the exposure measured to minimise bias? 
 Yes  
 Can’t Tell 
 No  
HINT: We are looking for measurement, recall or classification bias  
• Was the exposure clearly defined and accurately measured? 
• Did the authors use subjective or objective measurements?  
• Do the measures truly reflect what they are supposed to measure (have they been 
validated)? 
• Were the measurement methods similar in the cases and controls? 
• Did the study incorporate blinding where feasible? 
• Is the temporal relation correct (does the exposure of interest precede the 
outcome)?  
6. (a) Aside from the experimental intervention, were the groups treated equally? 
 Yes  
 Can’t Tell 
 No 
HINT: List the ones you think might be important, that the author may have missed  
• Genetic  
• Environmental  
• Socio-economic  
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6. (b) Have the authors taken account of the potential confounding factors in the design 
and/or in their analysis? 
 Yes  
 Can’t Tell 
 No 
HINT: Look for  
• Restriction in design, and techniques (e.g. modelling, stratified-, regression-, or 
sensitivity analysis to correct, control or adjust for confounding factors)  
 
Section B: What are the results? 
7. How large was the treatment effect? 
HINT: Consider  
• What are the bottom line results?  
• Is the analysis appropriate to the design?  
• How strong is the association between exposure and outcome (look at the odds 
ratio)?  
• Are the results adjusted for confounding, and might confounding still explain the 
association? 
• Has adjustment made a big difference to the OR?  
8. How precise was the estimate of the treatment effect? 
HINT: Consider  
• Size of the p-value  
• Size of the confidence intervals  
• Have the authors considered all the important variables?  
• How was the effect of subjects refusing to participate evaluated?  
9. Do you believe the results?  
 Yes  
 Can’t Tell 
 No 
HINT: Consider  
• Big effect is hard to ignore!  
• Can it be due to chance, bias, or confounding?  




• Consider Bradford Hills criteria (e.g. time sequence, does-response gradient, 
strength, biological plausibility)  
 
Section C: Will the results help locally? 
10. Can the results be applied to the local population? 
 Yes  
 Can’t Tell 
 No 
HINT: Consider whether  
• The subjects covered in the study could be sufficiently different from your 
population to cause concern  
• Your local setting is likely to differ much from that of the study  
• Can you quantify the local benefits and harms?  
11. Do the results of this study fit with other available evidence? 
 Yes  
 Can’t Tell 
 No 
HINT: Consider  
• All the available evidence from RCT’s Systematic Reviews, Cohort Studies, and Case 




Appendix D – Flow diagram showing study selection  
 
 
Records identified through 
MEDLINE, Embase, and the 
Cochrane Library 
(n = 165) 
Records after duplicates removed 
(n = 15) 
Full-text articles assessed 
for eligibility  
(n = 15) 
Records screened 
(n = 25) 
Studies included in 
qualitative synthesis 
(n = 17) 
Full-text articles excluded, 
with reasons  
(n = 3) 
• No data on cleft (2) 
• Review paper (1) 
Additional records 
identified through other 
sources 
(n = 5) 
 
(n = 0) 
 
Studies included in 
quantitative synthesis 
(n = 8) 
